carbon monoxide has been researched along with Lung Diseases in 227 studies
Carbon Monoxide: Carbon monoxide (CO). A poisonous colorless, odorless, tasteless gas. It combines with hemoglobin to form carboxyhemoglobin, which has no oxygen carrying capacity. The resultant oxygen deprivation causes headache, dizziness, decreased pulse and respiratory rates, unconsciousness, and death. (From Merck Index, 11th ed)
carbon monoxide : A one-carbon compound in which the carbon is joined only to a single oxygen. It is a colourless, odourless, tasteless, toxic gas.
Lung Diseases: Pathological processes involving any part of the LUNG.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Carbon monoxide (CO) can exert potent anti-inflammatory effects in animal and cell culture models of sepsis, despite well-known lethal effects at high concentration." | 8.84 | Cytoprotective and anti-inflammatory actions of carbon monoxide in organ injury and sepsis models. ( Choi, AM; Ryter, SW, 2007) |
| "The aim of this study is to investigate the effect of heme oxygenase-1 (HO-1)/carbon monoxide (CO) system in pulmonary ischemia-reperfusion injury (PIRI) in rabbits." | 7.75 | Role of heme oxygenase-1/carbon monoxide system in pulmonary ischemia-reperfusion injury. ( Jia, X; Lin, L; Shi, L; Wang, F; Wang, W, 2009) |
| "The diffusing capacity for carbon monoxide (DLCO) and the functional residual capacity (FRC) of the lung were measured in 5 healthy Thoroughbreds before and after instillation of autologous blood into their lungs, in an attempt to develop a method to quantitate extravascular blood in the lungs of horses with exercise-induced pulmonary hemorrhage." | 7.69 | Evaluation of a technique for detection of pulmonary hemorrhage in horses, using carbon monoxide uptake. ( Aguilera-Tejero, E; Pascoe, JR; Smith, BL; Tyler, WS; Woliner, MJ, 1994) |
| "Smokers with chronic obstructive pulmonary disease (COPD) have particular difficulty quitting." | 6.87 | Effect of Long-term Nicotine Replacement Therapy vs Standard Smoking Cessation for Smokers With Chronic Lung Disease: A Randomized Clinical Trial. ( Ellerbeck, EF; Fitzgerald, SA; Hutcheson, TD; Nollen, N; Phadnis, M; Richter, KP; Salzman, GA; Sharpe, MR; Vacek, J, 2018) |
| "In eight patients with Goodpasture's syndrome the ratio ranged from 1." | 5.26 | Detection of intrapulmonary hemorrhage with carbon monoxide uptake. Application in goodpasture's syndrome. ( Ewan, PW; Hughes, JM; Jones, HA; Rhodes, CG, 1976) |
| "Thirty-nine sarcoidosis patients with pulmonary infiltrations (stage II) of less than 5 years duration and not treated earlier with corticosteroids were randomly allocated for treatment with methylprednisolone for 7 months or for observation without therapy." | 5.04 | Corticosteroid therapy of pulmonary sarcoidosis. A prospective evaluation of alternate day and daily dosage in stage II disease. ( Sellergren, TL; Selroos, O, 1979) |
| "Carbon monoxide (CO) can exert potent anti-inflammatory effects in animal and cell culture models of sepsis, despite well-known lethal effects at high concentration." | 4.84 | Cytoprotective and anti-inflammatory actions of carbon monoxide in organ injury and sepsis models. ( Choi, AM; Ryter, SW, 2007) |
| "1% during follow-up, and it was significantly associated to digital ulcers, interstitial lung disease, reduction of diffusion lung of carbon monoxide <75%, teleangectasias and melanodermia, while sicca syndrome and arthralgias were associated to normal/nonspecific pattern." | 3.81 | Prevalence and evolution of scleroderma pattern at nailfold videocapillaroscopy in systemic sclerosis patients: Clinical and prognostic implications. ( Campomori, F; Colaci, M; Ferri, C; Ghizzoni, C; Giuggioli, D; Manfredi, A; Sebastiani, M, 2015) |
| "The aim of this study is to investigate the effect of heme oxygenase-1 (HO-1)/carbon monoxide (CO) system in pulmonary ischemia-reperfusion injury (PIRI) in rabbits." | 3.75 | Role of heme oxygenase-1/carbon monoxide system in pulmonary ischemia-reperfusion injury. ( Jia, X; Lin, L; Shi, L; Wang, F; Wang, W, 2009) |
| " In multivariate analysis, chronic graft-versus-host disease (relative risk, 16) and pretransplantation diffusion capacity for carbon monoxide or forced expiratory volume in the first second <80% predicted were independently associated with a late decrease in PF from baseline (relative risk, 7)." | 3.73 | Chronic GVHD and pretransplantation abnormalities in pulmonary function are the main determinants predicting worsening pulmonary function in long-term survivors after stem cell transplantation. ( Barrett, AJ; Childs, R; Karimpour, S; Mielke, S; Montero, A; Rezvani, K; Savani, BN; Shenoy, A; Singh, A; Srinivasan, R, 2006) |
| "Positive associations, weakly significant and consistent across lags, were observed between asthma consultations and nitrogen dioxide (NO2) and carbon monoxide (CO) in children and particulate matter of less than 10 microm in diameter (PM10) in adults, and between other LRD consultations and sulphur dioxide (SO2) in children." | 3.70 | Association of air pollution with daily GP consultations for asthma and other lower respiratory conditions in London. ( Anderson, HR; Atkinson, RW; Goubet, SA; Haines, A; Hajat, S, 1999) |
| "Cardiac enlargement in chronic heart failure appears to be involved in causing restrictive lung pattern and a reduced alveolar volume that disturbs carbon monoxide diffusion." | 3.70 | Cardiomegaly as a possible cause of lung dysfunction in patients with heart failure. ( Agostoni, P; Bussotti, M; Cattadori, G; Guazzi, M; Marenzi, G; Palermo, P, 2000) |
| "The diffusing capacity for carbon monoxide (DLCO) and the functional residual capacity (FRC) of the lung were measured in 5 healthy Thoroughbreds before and after instillation of autologous blood into their lungs, in an attempt to develop a method to quantitate extravascular blood in the lungs of horses with exercise-induced pulmonary hemorrhage." | 3.69 | Evaluation of a technique for detection of pulmonary hemorrhage in horses, using carbon monoxide uptake. ( Aguilera-Tejero, E; Pascoe, JR; Smith, BL; Tyler, WS; Woliner, MJ, 1994) |
| "Serial changes in carbon monoxide uptake (KCO or DLCO/VA) were used to monitor episodes of pulmonary capillary haemorrhage in Goodpasture's syndrome (13 cases), immune complex nephritis (three cases) and idiopathic haemosiderosis (one case)." | 3.66 | The chest X-ray in pulmonary capillary haemorrhage: correlation with carbon monoxide uptake. ( Bowley, NB; Hughes, JM; Steiner, RE, 1979) |
| "Ventilatory function and carbon monoxide transfer factor were studied in nine adult patients with post-tricuspid intracardiac defects and the Eisenmenger syndrome." | 3.66 | Ventilatory function in the Eisenmenger syndrome. ( Gibson, GJ; Hunter, D; MacArthur, CG, 1979) |
| "Smokers with chronic obstructive pulmonary disease (COPD) have particular difficulty quitting." | 2.87 | Effect of Long-term Nicotine Replacement Therapy vs Standard Smoking Cessation for Smokers With Chronic Lung Disease: A Randomized Clinical Trial. ( Ellerbeck, EF; Fitzgerald, SA; Hutcheson, TD; Nollen, N; Phadnis, M; Richter, KP; Salzman, GA; Sharpe, MR; Vacek, J, 2018) |
| "The elevated risk of chronic obstructive pulmonary disease in PWH has been widely recognized, but PWH are also at higher risk for asthma and worse asthma outcomes." | 2.72 | Recent advances in HIV-associated chronic lung disease clinical research. ( Kunisaki, KM, 2021) |
| "Carbon monoxide (CO) is an endogenously produced gas that has gained recognition as a biological signal transduction effector with properties similar, but not identical, to that of nitric oxide (NO)." | 2.58 | Carbon monoxide in lung cell physiology and disease. ( Choi, AMK; Ma, KC; Ryter, SW, 2018) |
| "Current invasive measures of pulmonary inflammation include markers in blood and airway effluent, with the cellular composition of tracheal fluid being the "gold standard"." | 2.43 | Exhaled breath measures of inflammation: are they useful in neonatal chronic lung disease? ( Andersen, CC; Harrison, CM, 2005) |
| "Chronic obstructive pulmonary disease (COPD) is characterized by systemic inflammation that usually is caused by exposure to noxious particles or gases." | 1.56 | The protective effects of thymoquinone on lung damage caused by cigarette smoke. ( Büyükoğlan, H; Gülmez, I; Sönmez, MF; Tutar, N; Yetkin, NA; Yilmaz, I, 2020) |
| "Diffuse bronchiectasis was the main finding." | 1.43 | Preclinical lung disease in early rheumatoid arthritis. ( Dorca, J; Luburich, P; Molina-Molina, M; Narvaez-Garcia, J; Nolla, JM; Robles-Perez, A; Rodriguez-Sanchon, B, 2016) |
| "Hospital admissions for RD including chronic obstructive pulmonary disease (COPD), asthma, and pneumonia, and ambient air pollution data levels for Kaohsiung were obtained for the period from 2006 to 2010." | 1.42 | Coarse Particulate Air Pollution Associated with Increased Risk of Hospital Admissions for Respiratory Diseases in a Tropical City, Kaohsiung, Taiwan. ( Cheng, MH; Chiu, HF; Yang, CY, 2015) |
| "Diagnosing and managing pulmonary disease usually requires judging lung function against predicted values." | 1.38 | Validation of lung function prediction equations from patient survival data. ( Cooper, B; Miller, MR; Ward, H, 2012) |
| "The 14 patients without emphysema had interstitial lung disease, pulmonary vascular disease, and other isolated findings." | 1.34 | Retrospective study of pulmonary function tests in patients presenting with isolated reduction in single-breath diffusion capacity: implications for the diagnosis of combined obstructive and restrictive lung disease. ( Aduen, JF; Alvarez, F; Biewend, M; Jolles, HI; Keller, CA; Mobin, SI; Venegas, C; Zisman, DA, 2007) |
| "In a model of acute lung injury in mice, CO blocked expression of Egr-1, a central mediator of inflammation, and decreased tissue damage; inhibition of PPARgamma abrogated both effects." | 1.33 | Carbon monoxide orchestrates a protective response through PPARgamma. ( Bach, FH; Bilban, M; Chin, BY; d'Avila, JC; Esterbauer, H; Ifedigbo, E; Otterbein, LE; Otterbein, SL; Robson, SC; Usheva, A; Wagner, O, 2006) |
| "Pulmonary complications of sickle cell anemia (Hb-SS) commonly cause morbidity, yet few large studies of pulmonary function tests (PFTs) in this population have been reported." | 1.33 | Abnormal pulmonary function in adults with sickle cell anemia. ( Klings, ES; Nolan, VG; Steinberg, MH; Wyszynski, DF, 2006) |
| "We selected a group of breast cancer patients in high-dose chemotherapy (HDCT) protocols who were at risk for pulmonary injury." | 1.33 | Intrabreath analysis of carbon monoxide uptake during exercise in patients at risk for lung injury. ( Folz, RJ; Huang, YC; Macintyre, NR; O'brien, SR; Vredenburgh, J, 2006) |
| " In three patients the pulmonary disorder seems to have been caused by a cell-mediated immunological side effect in the form of interstitial pneumonitis." | 1.32 | Pulmonary side effects of interferon-alpha therapy in patients with hematological malignancies. ( Anderson, P; Höglund, M; Rödjer, S, 2003) |
| "Carbon monoxide (CO) has long been considered a toxic substance." | 1.32 | [The effects of inhaled carbon monoxide on lung injury in rats caused by lipopolysaccharide]. ( Fujimoto, J; Kudoh, I; Miyazaki, H; Ohta, M; Tazawa, T; Yamada, H, 2003) |
| "A diffuse nonspecific interstitial pneumonitis was present in lungs of immunodeficient mice, and flow cytometry indicated that both lymphocytes and macrophages were activated." | 1.30 | Pulmonary mechanical and immunologic dysfunction in a murine model of AIDS. ( Cohen, DA; Gillespie, MN; Hartsfield, CL; Lai, YL; Lipke, D, 1997) |
| "However, proteinuria was the only significant independent predictor of DLCO/VA." | 1.30 | Reduction of diffusion capacity for carbon monoxide in diabetic patients. ( Car, N; Drazić, Z; Ljubić, S; Metelko, Z; Roglić, G, 1998) |
| "Pulmonary disease is responsible for considerable morbidity and mortality in systemic sclerosis (SSc)." | 1.29 | Early pulmonary disease in systemic sclerosis: a comparison between carbon monoxide transfer factor and static lung compliance. ( Akesson, A; Scheja, A; Wollheim, FA; Wollmer, P, 1993) |
| "Treatment with nifedipine did not significantly change any of the pulmonary function values, except for the carbon monoxide diffusing capacity (DLCO)." | 1.28 | Diffusing capacity of the lung and nifedipine in systemic sclerosis. ( Georgiakodis, F; Kyriakidis, M; Papazoglou, S; Sfikakis, P; Sfikakis, PP; Toutouzas, P; Vergos, C, 1990) |
| "Thirty patients with cancer of the esophagus were treated with multimodality therapy." | 1.27 | Pulmonary complications of multimodality therapy for esophageal carcinoma. ( Chalaoui, J; Duprat, G; Duranceau, A; Robidoux, A; Sylvestre, J, 1987) |
| "In patients with pulmonary disease, the diffusing capacity for carbon monoxide has been used to predict abnormal gas exchange in the lung." | 1.27 | Diffusing capacity for carbon monoxide as a predictor of gas exchange during exercise. ( Hansen, JE; Oren, A; Sue, DY; Wasserman, K, 1987) |
| "In eight patients with Goodpasture's syndrome the ratio ranged from 1." | 1.26 | Detection of intrapulmonary hemorrhage with carbon monoxide uptake. Application in goodpasture's syndrome. ( Ewan, PW; Hughes, JM; Jones, HA; Rhodes, CG, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 100 (44.05) | 18.7374 |
| 1990's | 26 (11.45) | 18.2507 |
| 2000's | 54 (23.79) | 29.6817 |
| 2010's | 40 (17.62) | 24.3611 |
| 2020's | 7 (3.08) | 2.80 |
| Authors | Studies |
|---|---|
| Davidow, K | 1 |
| Bunin, N | 1 |
| Goldfarb, S | 1 |
| Li, Y | 1 |
| Freedman, JL | 1 |
| Byanova, KL | 1 |
| Fitzpatrick, J | 1 |
| Jan, AK | 1 |
| McGing, M | 1 |
| Hartman-Filson, M | 1 |
| Farr, CK | 1 |
| Zhang, M | 1 |
| Gardner, K | 1 |
| Branchini, J | 1 |
| Kerruish, R | 1 |
| Bhide, S | 1 |
| Bates, A | 1 |
| Hsieh, J | 1 |
| Abelman, R | 1 |
| Hunt, PW | 1 |
| Wang, RJ | 1 |
| Crothers, KA | 1 |
| Huang, L | 2 |
| Rylance, S | 1 |
| Nightingale, R | 1 |
| Naunje, A | 1 |
| Mbalume, F | 1 |
| Jewell, C | 1 |
| Balmes, JR | 1 |
| Grigg, J | 1 |
| Mortimer, K | 1 |
| Yetkin, NA | 1 |
| Büyükoğlan, H | 1 |
| Sönmez, MF | 1 |
| Tutar, N | 1 |
| Gülmez, I | 1 |
| Yilmaz, I | 1 |
| Qin, S | 1 |
| Vodovotz, L | 1 |
| Zamora, R | 1 |
| Fitzpatrick, M | 1 |
| Kessinger, C | 1 |
| Kingsley, L | 1 |
| McMahon, D | 1 |
| DeSensi, R | 1 |
| Leader, JK | 1 |
| Crothers, K | 1 |
| Morris, A | 2 |
| Nouraie, M | 2 |
| Kunisaki, KM | 2 |
| Jensen, RL | 1 |
| Chang, D | 1 |
| D'Souza, G | 1 |
| Fitzpatrick, ME | 1 |
| McCormack, MC | 1 |
| Stosor, V | 1 |
| Choudhari, OK | 1 |
| Ojha, UC | 1 |
| Gothi, D | 1 |
| Spalgais, S | 1 |
| Singh, P | 1 |
| Rani, A | 1 |
| Singh, A | 2 |
| Kesavachandran, CN | 1 |
| Kamal, R | 1 |
| Bihari, V | 1 |
| Ansari, A | 1 |
| Azeez, PA | 1 |
| Saxena, PN | 1 |
| Ks, AK | 1 |
| Khan, AH | 1 |
| Taguchi, K | 1 |
| Yamasaki, K | 1 |
| Sakai, H | 1 |
| Maruyama, T | 1 |
| Otagiri, M | 1 |
| Ryter, SW | 7 |
| Ma, KC | 1 |
| Choi, AMK | 1 |
| Bernhard, N | 1 |
| Lepper, PM | 1 |
| Vogelmeier, C | 1 |
| Seibert, M | 1 |
| Wagenpfeil, S | 1 |
| Bals, R | 1 |
| Fähndrich, S | 1 |
| Yamaguchi, K | 1 |
| Tsuji, T | 1 |
| Aoshiba, K | 1 |
| Nakamura, H | 1 |
| Öztürk, A | 1 |
| Kayacan, O | 1 |
| Ellerbeck, EF | 1 |
| Nollen, N | 1 |
| Hutcheson, TD | 1 |
| Phadnis, M | 1 |
| Fitzgerald, SA | 1 |
| Vacek, J | 1 |
| Sharpe, MR | 1 |
| Salzman, GA | 1 |
| Richter, KP | 1 |
| Shafran, I | 1 |
| Lang, IM | 1 |
| Kaminsky, DA | 1 |
| Jarzembowski, SC | 1 |
| Klasen, E | 1 |
| Miranda, JJ | 1 |
| Khatry, S | 1 |
| Menya, D | 1 |
| Gilman, RH | 1 |
| Tielsch, JM | 1 |
| Kennedy, C | 1 |
| Dreibelbis, R | 1 |
| Naithani, N | 1 |
| Kimaiyo, S | 1 |
| Chiang, M | 1 |
| Carter, EJ | 1 |
| Sherman, CB | 1 |
| Breysse, PN | 1 |
| Checkley, W | 1 |
| Degano, B | 1 |
| Perrin, F | 1 |
| Soumagne, T | 1 |
| Agard, C | 1 |
| Chambellan, A | 1 |
| Takai, D | 1 |
| Tsai, SS | 1 |
| Chiu, HF | 2 |
| Liou, SH | 1 |
| Yang, CY | 2 |
| Ghizzoni, C | 1 |
| Sebastiani, M | 1 |
| Manfredi, A | 1 |
| Campomori, F | 1 |
| Colaci, M | 1 |
| Giuggioli, D | 1 |
| Ferri, C | 1 |
| Cheng, MH | 1 |
| Robles-Perez, A | 1 |
| Luburich, P | 1 |
| Rodriguez-Sanchon, B | 1 |
| Dorca, J | 1 |
| Nolla, JM | 1 |
| Molina-Molina, M | 1 |
| Narvaez-Garcia, J | 1 |
| Veiga, CS | 1 |
| Coutinho, DS | 1 |
| Nakaie, CM | 1 |
| Campos, LM | 1 |
| Suzuki, L | 1 |
| Cunha, MT | 1 |
| Leone, C | 1 |
| Silva, CA | 1 |
| Rodrigues, JC | 1 |
| Franzen, D | 1 |
| Ciurea, A | 1 |
| Bratton, DJ | 1 |
| Clarenbach, CF | 1 |
| Latshang, TD | 1 |
| Russi, EW | 1 |
| Kyburz, D | 1 |
| Kohler, M | 1 |
| Rizzi, M | 1 |
| Tarsia, P | 1 |
| La Spina, T | 1 |
| Cristiano, A | 1 |
| Frassanito, F | 1 |
| Macaluso, C | 1 |
| Airoldi, A | 1 |
| Vanni, S | 1 |
| Legnani, D | 1 |
| Alam, A | 1 |
| Tawale, N | 1 |
| Patel, A | 1 |
| Dibley, MJ | 1 |
| Jadhao, S | 1 |
| Raynes-Greenow, C | 1 |
| Guidotti, F | 1 |
| Piatti, G | 1 |
| Marcon, A | 1 |
| Cassinerio, E | 1 |
| Giuditta, M | 1 |
| Roghi, A | 1 |
| Fasano, V | 1 |
| Consonni, D | 1 |
| Cappellini, MD | 1 |
| Zavorsky, GS | 1 |
| van der Lee, I | 3 |
| Graham, BL | 1 |
| Brusasco, V | 1 |
| Burgos, F | 1 |
| Cooper, BG | 1 |
| Jensen, R | 1 |
| Kendrick, A | 1 |
| MacIntyre, NR | 2 |
| Thompson, BR | 1 |
| Wanger, J | 1 |
| Crapo, RO | 1 |
| Plummer, AL | 1 |
| Eichinger, M | 1 |
| Walterspacher, S | 1 |
| Scholz, T | 1 |
| Tetzlaff, K | 1 |
| Röcker, K | 1 |
| Muth, CM | 1 |
| Puderbach, M | 1 |
| Kauczor, HU | 1 |
| Sorichter, S | 1 |
| Owens, RL | 1 |
| Yim-Yeh, S | 1 |
| Malhotra, A | 1 |
| Gläser, S | 2 |
| Meyer, R | 1 |
| Opitz, CF | 1 |
| Hetzer, R | 1 |
| Ewert, R | 2 |
| Uzma, N | 1 |
| Salar, BM | 1 |
| Kumar, BS | 1 |
| Aziz, N | 1 |
| David, MA | 1 |
| Reddy, VD | 1 |
| Vos, R | 1 |
| Cordemans, C | 1 |
| Vanaudenaerde, BM | 1 |
| De Vleeschauwer, SI | 1 |
| Schoonis, A | 1 |
| Van Raemdonck, DE | 1 |
| Dupont, LJ | 1 |
| Verleden, GM | 1 |
| Wang, W | 1 |
| Wang, F | 1 |
| Shi, L | 1 |
| Jia, X | 1 |
| Lin, L | 1 |
| Amar, D | 1 |
| Munoz, D | 1 |
| Shi, W | 1 |
| Zhang, H | 1 |
| Thaler, HT | 1 |
| Ghosh, S | 1 |
| Gal, J | 1 |
| Marczin, N | 1 |
| Chen, R | 1 |
| Pan, G | 1 |
| Kan, H | 1 |
| Tan, J | 1 |
| Song, W | 1 |
| Wu, Z | 1 |
| Xu, X | 1 |
| Xu, Q | 1 |
| Jiang, C | 1 |
| Chen, B | 1 |
| Celebi Sözener, Z | 1 |
| Karabıyıkoğlu, G | 1 |
| Düzgün, N | 1 |
| Gajdócsy, R | 1 |
| Horváth, I | 2 |
| Süyür, H | 1 |
| Bayram, N | 1 |
| Aydın, N | 1 |
| Uyar, M | 1 |
| Gündoğdu, N | 1 |
| Elbek, O | 1 |
| Budinger, GR | 1 |
| Mutlu, GM | 1 |
| Ward, H | 1 |
| Cooper, B | 1 |
| Miller, MR | 1 |
| Schmidt, R | 2 |
| Chow, S | 1 |
| Thomas, PS | 1 |
| Malouf, M | 1 |
| Yates, DH | 1 |
| Hughes, JM | 7 |
| Pride, NB | 1 |
| Zhou, M | 1 |
| Liu, Y | 1 |
| Duan, Y | 1 |
| Lawson, K | 1 |
| Maher, TM | 1 |
| Hansell, DM | 1 |
| Nicholson, AG | 1 |
| Holtfreter, B | 1 |
| Richter, S | 1 |
| Kocher, T | 1 |
| Dörr, M | 1 |
| Völzke, H | 1 |
| Ittermann, T | 1 |
| Obst, A | 1 |
| Schäper, C | 1 |
| John, U | 1 |
| Meisel, P | 1 |
| Grotevendt, A | 1 |
| Felix, SB | 1 |
| Agostoni, PG | 1 |
| Bussotti, M | 2 |
| Palermo, P | 2 |
| Guazzi, M | 2 |
| Paredi, P | 1 |
| Kharitonov, SA | 3 |
| Barnes, PJ | 4 |
| Anderson, P | 1 |
| Höglund, M | 1 |
| Rödjer, S | 1 |
| Miyazaki, H | 1 |
| Yamada, H | 1 |
| Ohta, M | 1 |
| Fujimoto, J | 1 |
| Tazawa, T | 1 |
| Kudoh, I | 1 |
| Slebos, DJ | 1 |
| Choi, AM | 11 |
| KJERULF-JENSEN, K | 1 |
| KRUHØFFER, P | 1 |
| KANAGAMI, H | 1 |
| KATSURA, T | 1 |
| SHIROISHI, K | 1 |
| BABA, K | 1 |
| EBINA, T | 1 |
| GARBAGNI, R | 1 |
| CARELLI, E | 1 |
| SMITH, JR | 1 |
| HAMILTON, LH | 1 |
| RANDOWA, D | 3 |
| SIERAWSKI, S | 1 |
| WOOLF, CR | 3 |
| BEUMER, HM | 1 |
| CHAPMAN, TT | 1 |
| WYNDER, EL | 1 |
| HOFFMANN, D | 1 |
| BJURE, J | 2 |
| Otterbein, LE | 3 |
| Otterbein, SL | 2 |
| Ifedigbo, E | 2 |
| Liu, F | 1 |
| Morse, DE | 1 |
| Fearns, C | 1 |
| Ulevitch, RJ | 1 |
| Knickelbein, R | 1 |
| Flavell, RA | 1 |
| RENARD, J | 1 |
| BESSE, J | 1 |
| Dolinay, T | 3 |
| Szilasi, M | 1 |
| Liu, M | 1 |
| Brook, RD | 1 |
| Franklin, B | 1 |
| Cascio, W | 1 |
| Hong, Y | 1 |
| Howard, G | 1 |
| Lipsett, M | 1 |
| Luepker, R | 1 |
| Mittleman, M | 1 |
| Samet, J | 1 |
| Smith, SC | 1 |
| Tager, I | 1 |
| Fitting, JW | 1 |
| Harrison, CM | 1 |
| Andersen, CC | 1 |
| Leitch, DN | 1 |
| Harkawat, R | 1 |
| Askew, J | 1 |
| Masel, P | 1 |
| Hendrick, DJ | 1 |
| Khanna, D | 1 |
| Clements, PJ | 1 |
| Furst, DE | 1 |
| Chon, Y | 1 |
| Elashoff, R | 1 |
| Roth, MD | 1 |
| Sterz, MG | 1 |
| Chung, J | 1 |
| FitzGerald, JD | 1 |
| Seibold, JR | 1 |
| Varga, J | 1 |
| Theodore, A | 1 |
| Wigley, FM | 1 |
| Silver, RM | 1 |
| Steen, VD | 1 |
| Mayes, MD | 1 |
| Connolly, MK | 1 |
| Fessler, BJ | 1 |
| Rothfield, NF | 1 |
| Mubarak, K | 1 |
| Molitor, J | 1 |
| Tashkin, DP | 2 |
| Morse, D | 3 |
| Thom, SR | 1 |
| Weaver, LK | 1 |
| Hampson, NB | 1 |
| Zanen, P | 1 |
| van den Bosch, JM | 1 |
| Lammers, JW | 1 |
| Ravipati, G | 1 |
| Aronow, WS | 2 |
| Sidana, J | 1 |
| Maguire, GP | 1 |
| McClung, JA | 1 |
| Belkin, RN | 1 |
| Lehrman, SG | 1 |
| Huang, YC | 1 |
| O'brien, SR | 1 |
| Vredenburgh, J | 1 |
| Folz, RJ | 1 |
| Brunelli, A | 1 |
| Refai, MA | 1 |
| Salati, M | 1 |
| Sabbatini, A | 1 |
| Morgan-Hughes, NJ | 1 |
| Rocco, G | 1 |
| Mishra, S | 1 |
| Fujita, T | 2 |
| Lama, VN | 1 |
| Nam, D | 1 |
| Liao, H | 1 |
| Okada, M | 1 |
| Minamoto, K | 1 |
| Yoshikawa, Y | 1 |
| Harada, H | 1 |
| Pinsky, DJ | 1 |
| Klings, ES | 1 |
| Wyszynski, DF | 1 |
| Nolan, VG | 1 |
| Steinberg, MH | 1 |
| Bilban, M | 1 |
| Bach, FH | 2 |
| d'Avila, JC | 1 |
| Esterbauer, H | 1 |
| Chin, BY | 1 |
| Usheva, A | 1 |
| Robson, SC | 1 |
| Wagner, O | 1 |
| Pramesh, CS | 1 |
| Mistry, RC | 1 |
| Laszlo, G | 1 |
| Krediet, TG | 1 |
| Cirkel, GA | 1 |
| Vreman, HJ | 1 |
| Wong, RJ | 1 |
| Stevenson, DK | 1 |
| Groenendaal, F | 1 |
| Egberts, J | 1 |
| Van Bel, F | 1 |
| Zhang, X | 1 |
| Shan, P | 1 |
| Jiang, G | 1 |
| Zhang, SS | 1 |
| Fu, XY | 1 |
| Lee, PJ | 1 |
| Savani, BN | 1 |
| Montero, A | 1 |
| Srinivasan, R | 1 |
| Shenoy, A | 1 |
| Mielke, S | 1 |
| Rezvani, K | 1 |
| Karimpour, S | 1 |
| Childs, R | 1 |
| Barrett, AJ | 1 |
| Aduen, JF | 1 |
| Zisman, DA | 1 |
| Mobin, SI | 1 |
| Venegas, C | 1 |
| Alvarez, F | 1 |
| Biewend, M | 1 |
| Jolles, HI | 1 |
| Keller, CA | 1 |
| Tiev, KP | 1 |
| Cabane, J | 1 |
| Aubourg, F | 1 |
| Kettaneh, A | 1 |
| Ziani, M | 1 |
| Mouthon, L | 1 |
| Duong-Quy, S | 1 |
| Fajac, I | 1 |
| Guillevin, L | 1 |
| Dinh-Xuan, AT | 1 |
| Chaouachi, K | 1 |
| Hoetzel, A | 1 |
| Kim, HP | 1 |
| Nakahira, K | 1 |
| Zuckerbraun, BS | 2 |
| Kaczorowski, DJ | 1 |
| Hatzfeld, C | 1 |
| Wiener, F | 1 |
| Briscoe, WA | 1 |
| James, F | 1 |
| Rumble, L | 1 |
| del Piano, M | 1 |
| La Palombara, P | 1 |
| Nicosia, R | 1 |
| Sessa, R | 1 |
| Luursema, PB | 1 |
| Star-Kroesen, MA | 1 |
| van der Mark, TW | 1 |
| Sleyfer, DT | 1 |
| Koops, HS | 1 |
| Peset, R | 1 |
| Horvath, SM | 1 |
| Effros, RM | 1 |
| Mason, GR | 1 |
| Lefcoe, NM | 1 |
| Ashley, MJ | 1 |
| Pederson, LL | 1 |
| Keays, JJ | 1 |
| Mookherjee, S | 1 |
| Ashutosh, K | 1 |
| Smulyan, H | 1 |
| Vardan, S | 1 |
| Warner, R | 1 |
| Murata, K | 1 |
| Todo, G | 1 |
| Senda, M | 1 |
| Tamaki, N | 1 |
| Yonekura, Y | 1 |
| Itoh, H | 1 |
| Mukai, T | 1 |
| Minato, K | 1 |
| Saji, H | 1 |
| Chu, SS | 1 |
| Cotes, JE | 1 |
| Collishaw, NE | 1 |
| Kirkbride, J | 1 |
| Wigle, DT | 1 |
| O'Brodovich, HM | 1 |
| Way, RC | 1 |
| Andrew, M | 1 |
| Dent, PB | 1 |
| Lloyd, MH | 1 |
| Gauld, S | 1 |
| Copland, L | 1 |
| Soutar, CA | 1 |
| Bils, RF | 1 |
| Christie, BR | 1 |
| Forster, RE | 1 |
| Ogilvie, C | 1 |
| Davies, NJ | 1 |
| Zamorano, T | 1 |
| Greening, AP | 1 |
| Lewis, SM | 1 |
| Rubin, DZ | 1 |
| Mittman, C | 1 |
| Hałuszka, J | 1 |
| Brański, H | 1 |
| Weinberger, SE | 1 |
| Johnson, TS | 1 |
| Weiss, ST | 1 |
| Muir, JF | 1 |
| Levi-Valensi, P | 1 |
| Vonachen, P | 1 |
| Smadja, A | 1 |
| Scheja, A | 1 |
| Akesson, A | 1 |
| Wollmer, P | 1 |
| Wollheim, FA | 1 |
| Kiss, D | 1 |
| Popp, W | 1 |
| Wagner, C | 1 |
| Havelec, L | 1 |
| Sertl, K | 1 |
| Bankier, AA | 1 |
| Kiener, HP | 1 |
| Wiesmayr, MN | 1 |
| Fleischmann, D | 1 |
| Kontrus, M | 1 |
| Herold, CJ | 1 |
| Graninger, W | 1 |
| Hübsch, P | 1 |
| Takahashi, H | 1 |
| Iwabuchi, K | 1 |
| Kudo, Y | 1 |
| Tomoike, H | 1 |
| Niizeki, K | 1 |
| Uchida, K | 1 |
| Takahashi, K | 1 |
| Wilson, AF | 1 |
| Hearne, J | 1 |
| Brenner, M | 1 |
| Alfonso, R | 1 |
| Aguilera-Tejero, E | 1 |
| Pascoe, JR | 1 |
| Smith, BL | 1 |
| Tyler, WS | 1 |
| Woliner, MJ | 1 |
| Kvale, PA | 1 |
| Rosen, MJ | 1 |
| Hopewell, PC | 1 |
| Markowitz, N | 1 |
| Hansen, N | 1 |
| Reichman, LB | 1 |
| Wallace, JM | 1 |
| Glassroth, J | 1 |
| Fulkerson, W | 1 |
| Meiselman, L | 1 |
| de los Santos-Sastre, S | 1 |
| Baylor, P | 1 |
| Goebel, P | 1 |
| Hazelrigg, S | 1 |
| Boley, T | 1 |
| Henkle, J | 1 |
| Lawyer, C | 1 |
| Johnstone, D | 1 |
| Naunheim, K | 1 |
| Keller, C | 1 |
| Keenan, R | 1 |
| Landreneau, R | 1 |
| Sciurba, F | 1 |
| Feins, R | 1 |
| Levy, P | 1 |
| Magee, M | 1 |
| Pribyl, CR | 1 |
| Racca, J | 1 |
| Lampert, E | 1 |
| Charloux, A | 1 |
| Lonsdorfer, J | 1 |
| Frans, A | 2 |
| Buyse, B | 1 |
| Demedts, M | 1 |
| Meekers, J | 1 |
| Vandegaer, L | 1 |
| Rochette, F | 1 |
| Kerkhofs, L | 1 |
| Hartsfield, CL | 1 |
| Lipke, D | 1 |
| Lai, YL | 1 |
| Cohen, DA | 1 |
| Gillespie, MN | 1 |
| Ishibashi, M | 1 |
| Yoshida, M | 1 |
| Nemery, B | 1 |
| Veriter, C | 1 |
| Lacquet, L | 1 |
| Francis, C | 1 |
| Melendez, JA | 1 |
| Barrera, R | 1 |
| Ljubić, S | 1 |
| Metelko, Z | 1 |
| Car, N | 1 |
| Roglić, G | 1 |
| Drazić, Z | 1 |
| Mueller, W | 1 |
| Schubert, J | 1 |
| Benzing, A | 1 |
| Geiger, K | 1 |
| Prescott, GJ | 1 |
| Cohen, GR | 1 |
| Elton, RA | 1 |
| Fowkes, FG | 1 |
| Agius, RM | 1 |
| Hajat, S | 1 |
| Haines, A | 1 |
| Goubet, SA | 1 |
| Atkinson, RW | 1 |
| Anderson, HR | 1 |
| de Jongste, JC | 1 |
| Alving, K | 1 |
| Bruce, N | 1 |
| Perez-Padilla, R | 1 |
| Albalak, R | 1 |
| Agostoni, P | 1 |
| Cattadori, G | 1 |
| Marenzi, G | 1 |
| Smidt, U | 2 |
| MacNee, W | 1 |
| Kelly, FJ | 1 |
| Dekhuijzen, PN | 1 |
| Phillips, M | 1 |
| Döring, G | 1 |
| Yamaya, M | 1 |
| Willis, D | 1 |
| Donnelly, LE | 1 |
| Chung, KF | 1 |
| Fan, M | 1 |
| Marks, LB | 1 |
| Lind, P | 1 |
| Hollis, D | 1 |
| Woel, RT | 1 |
| Bentel, GG | 1 |
| Anscher, MS | 1 |
| Shafman, TD | 1 |
| Coleman, RE | 1 |
| Jaszczak, RJ | 1 |
| Munley, MT | 1 |
| Chapman, JT | 1 |
| Dimopoulou, I | 1 |
| Galani, H | 1 |
| Dafni, U | 1 |
| Samakovii, A | 1 |
| Roussos, C | 1 |
| Dimopoulos, MA | 1 |
| Zhou, JL | 1 |
| Ling, YL | 1 |
| Jin, GH | 1 |
| Zhang, JL | 1 |
| Shi, ZL | 1 |
| Huang, XL | 1 |
| Clark, EH | 1 |
| Jones, HA | 2 |
| Kimura, K | 1 |
| Rikitake, T | 1 |
| Matsumoto, T | 1 |
| Tateno, Y | 1 |
| Hasegawa, S | 1 |
| Miller, GH | 1 |
| Hallenborg, C | 1 |
| Holden, W | 1 |
| Menzel, T | 1 |
| Dozor, R | 1 |
| Nadel, JA | 1 |
| Bowley, NB | 1 |
| Steiner, RE | 1 |
| MacArthur, CG | 1 |
| Hunter, D | 1 |
| Gibson, GJ | 1 |
| Selroos, O | 1 |
| Sellergren, TL | 1 |
| Lipscomb, DJ | 1 |
| Patel, K | 1 |
| Ewan, PW | 2 |
| Rees, AJ | 1 |
| Rhodes, CG | 1 |
| Miller, A | 1 |
| Chuang, M | 1 |
| Teirstein, AS | 1 |
| Siltzbach, LE | 1 |
| Salorinne, Y | 1 |
| Siemon, G | 1 |
| Gorelick, D | 1 |
| Khalsa, ME | 1 |
| Simmons, M | 1 |
| Chang, P | 1 |
| Haydock, DA | 1 |
| Trulock, EP | 1 |
| Kaiser, LR | 1 |
| Knight, SR | 1 |
| Pasque, MK | 1 |
| Cooper, JD | 1 |
| Cooke, TF | 1 |
| Kelly, C | 1 |
| Gardiner, P | 1 |
| Pal, B | 1 |
| Griffiths, I | 1 |
| Sfikakis, PP | 1 |
| Kyriakidis, M | 1 |
| Vergos, C | 1 |
| Papazoglou, S | 1 |
| Georgiakodis, F | 1 |
| Toutouzas, P | 1 |
| Sfikakis, P | 1 |
| Duprat, G | 1 |
| Chalaoui, J | 1 |
| Sylvestre, J | 1 |
| Robidoux, A | 1 |
| Duranceau, A | 1 |
| Rylander, R | 1 |
| Bake, B | 1 |
| Fischer, JJ | 1 |
| Helander, IM | 1 |
| Sprince, NL | 1 |
| Oliver, LC | 1 |
| Eisen, EA | 1 |
| Greene, RE | 1 |
| Chamberlin, RI | 1 |
| Ameratunga, R | 1 |
| Harris, EA | 1 |
| Sue, DY | 1 |
| Oren, A | 1 |
| Hansen, JE | 1 |
| Wasserman, K | 1 |
| Songco, G | 1 |
| Fahey, PJ | 1 |
| Ekholdt, PF | 1 |
| Gulsvik, A | 1 |
| Digranes, S | 1 |
| Hovig, T | 1 |
| Mellbye, OJ | 1 |
| Talseth, T | 1 |
| Ashitaka, T | 1 |
| Suzuki, T | 1 |
| Iio, M | 1 |
| Bréant, J | 1 |
| Fleury, MF | 1 |
| van Lerberghe, A | 1 |
| Maurique, S | 1 |
| Frutiger, F | 1 |
| Blin, C | 1 |
| Sirota, AD | 1 |
| Curran, JP | 1 |
| Habif, V | 1 |
| Petrilli, FL | 1 |
| Kanitz, S | 1 |
| Löllgen, H | 1 |
| von Nieding, G | 1 |
| Krekeler, H | 1 |
| Rubin, G | 1 |
| Baume, P | 1 |
| Vandenberg, R | 1 |
| Bachofen, H | 1 |
| Scherrer, M | 1 |
| Lewis, TR | 1 |
| Moorman, WJ | 1 |
| Ludmann, WF | 1 |
| Campbell, KI | 1 |
| Ayotte, B | 1 |
| Friesen, WO | 1 |
| Rosenhamer, G | 1 |
| McIlroy, MB | 1 |
| Keller, R | 2 |
| Graf, W | 1 |
| Mahlich, J | 2 |
| Herzog, H | 2 |
| Uzawa, T | 1 |
| Osada, H | 1 |
| Isoyama, Y | 1 |
| Nonaka, T | 1 |
| Tajima, G | 1 |
| Emirgil, C | 1 |
| Sobol, BJ | 1 |
| Heymann, B | 1 |
| Shibutani, K | 1 |
| Sundström, G | 1 |
| Wolkonsky, PM | 1 |
| Daly, WJ | 1 |
| West, JB | 2 |
| Bernard, JP | 1 |
| Touraine, R | 1 |
| Gracey, DR | 1 |
| Divertie, MB | 1 |
| Brown, AL | 1 |
| Schlipköter, HW | 1 |
| Bruch, J | 1 |
| Brockhaus, A | 1 |
| Fodor, GG | 1 |
| Sackner, MA | 1 |
| Raskin, MM | 1 |
| Julien, PJ | 1 |
| Avery, WG | 1 |
| Harrison, BD | 1 |
| Gregory, RJ | 1 |
| Clark, TJ | 1 |
| Scott, GW | 1 |
| Vorob'eva, ZV | 1 |
| Khabakov, AI | 1 |
| Vandenbergh, E | 1 |
| Billiet, L | 1 |
| Van de Woestijne, KP | 1 |
| Gyselen, A | 1 |
| Gabriel, S | 1 |
| Kreukniet, J | 1 |
| Alarie, Y | 1 |
| Ulrich, CE | 1 |
| Busey, WM | 1 |
| Swann, HE | 1 |
| MacFarland, HN | 1 |
| Lopez-Majano, V | 1 |
| Mitchell, MM | 1 |
| Renzetti, AD | 1 |
| Desbaumes, P | 1 |
| Foreman, S | 1 |
| Weill, H | 1 |
| Duke, R | 1 |
| George, R | 1 |
| Ziskind, M | 1 |
| Cleary, GJ | 1 |
| Blackburn, RB | 1 |
| Rzeszutko, B | 1 |
| Söderholm, B | 1 |
| MacIntyre, J | 1 |
| Norman, JN | 1 |
| Smith, G | 1 |
| Schlueter, DP | 1 |
| Fink, JN | 1 |
| Sosman, AJ | 1 |
| Holmgren, A | 1 |
| Svanborg, N | 1 |
| Isawa, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Smoking Cessation Versus Long-term Nicotine Replacement Among High-risk Smokers[NCT02148445] | Phase 3 | 398 participants (Actual) | Interventional | 2014-05-31 | Completed | ||
| Feasibility Intervention Trial of Two Types of Improved Cookstoves in Three Developing Countries[NCT01686867] | 137 participants (Actual) | Interventional | 2012-04-30 | Completed | |||
| The Association of Cigarette Smoking on Exercise Capacity and Skeletal Muscle Function in Taiwan Adult Smokers[NCT04688177] | 52 participants (Actual) | Observational | 2020-12-03 | Completed | |||
| iLiFE: a Home-based Physical Activity Programme for Patients With Advanced Interstitial Lung Diseases[NCT04224233] | 100 participants (Anticipated) | Interventional | 2020-10-01 | Recruiting | |||
| Pulmonary Abnormalities, Diastolic Dysfunction, and World Trade Center Exposure: Implications for Diagnosis and Treatment[NCT01466218] | 1,012 participants (Actual) | Observational | 2011-11-30 | Completed | |||
| Measuring Knowledge and Behavior After an Educational Program on Air Pollution as a Health Risk Reduction Strategy[NCT04563052] | 40 participants (Actual) | Interventional | 2020-01-28 | Completed | |||
| Mycophenolate vs. Oral Cyclophosphamide in Scleroderma Interstitial Lung Disease (Scleroderma Lung Study II)[NCT00883129] | Phase 2 | 142 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| Aerobic Physical Fitness and Health-related Quality of Life in Children With Sickle Cell Disease.[NCT05995743] | 72 participants (Actual) | Observational | 2021-11-01 | Completed | |||
| Inspiratory Muscle Training Effects on Pulmonary Function and Quality of Life in Children With Chest Burn[NCT05603507] | 40 participants (Actual) | Interventional | 2021-09-10 | Completed | |||
| Comparing Exercise Capacity in Patients With COPD Using High Flow Nasal Cannula Oxygen vs The Venturi Mask[NCT02858960] | 28 participants (Actual) | Interventional | 2016-04-30 | Completed | |||
| High Flow Nasal Cannula Versus The Venturi Mask During Exercise Training in Chronic Obstructive Pulmonary Disease Patients, a Randomized, Simple Blind, Controlled Trial.[NCT02973945] | 60 participants (Anticipated) | Interventional | 2017-07-01 | Recruiting | |||
| Exercise Capacity Testing in COPD Patients With High Flow Nasal Cannula[NCT02860273] | 28 participants (Actual) | Interventional | 2016-04-30 | Completed | |||
| Guangzhou Institute of Respiratory Disease[NCT02315547] | 120 participants (Anticipated) | Interventional | 2015-01-31 | Recruiting | |||
| Bacteriology and Sputum and Systemic Inflammation in Steady-state, Acute Exacerbation and Recovery of Bronchiectasis[NCT01761214] | 80 participants (Anticipated) | Interventional | 2012-09-30 | Recruiting | |||
| Phase II Trial of Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for Treatment of Bronchiolitis Obliterans Syndrome[NCT01287078] | Phase 2 | 25 participants (Actual) | Interventional | 2011-01-29 | Completed | ||
| [NCT00005273] | 0 participants | Observational | 1987-09-30 | Completed | |||
| Efficacy and Safety of Fluticasone Furoate/Vilanterol vs. Umeclidinium/Vilanterol in Patients With COPD-asthma Phenotype vs. Emphysema Phenotype. A Controled Clinical Trial.[NCT05342558] | Phase 4 | 133 participants (Actual) | Interventional | 2017-09-19 | Completed | ||
| Evaluating the Relationship Between Environmental Risk Factors in Housing Types and Chronic Respiratory Diseases in Ho Chi Minh City[NCT02898129] | 1,500 participants (Actual) | Interventional | 2016-09-30 | Completed | |||
| Efficacy and Acute Effects on Walked Distance froM basEline and Post Dose of indacateRol vs Tiotropium in Women With modeRAte to Severe COPD Secondary to Biomass Exposure: Open Label Crossover Clinical Trial[NCT02473237] | Phase 4 | 40 participants (Anticipated) | Interventional | 2013-04-30 | Completed | ||
| Efficacy and Safety of Indacaterol vs tiotropiuM on walkEd Distance From Baseline to 24 Weeks, in Women With modeRAte-severe COPD Secondary to Biomass Exposure: Randomized, Non Inferior, Open Label, Parallel Groups Clinical Trial[NCT05506865] | Phase 4 | 97 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
| Exhaled Breath Condensate (EBC) Collection and Analysis in Mechanically Ventilated ICU Patients: Monitoring of the Influence of Various Tidal Volumes on Lung Inflammatory Biomarkers[NCT00910026] | 20 participants (Anticipated) | Interventional | 2009-05-31 | Completed | |||
| Intensity Modulated Radiation Therapy for Breast Cancer: A Phase I Feasibility Study[NCT00594477] | Phase 1 | 100 participants (Actual) | Interventional | 2008-01-04 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in respiratory function, as measured by spirometry (FEV1), at 12 months post-randomization. (NCT02148445)
Timeframe: Month 12
| Intervention | % of predicted (Mean) |
|---|---|
| Standard Smoking Cessation | 55.4 |
| Extended Nicotine Replacement Therapy | 56.8 |
7-day point prevalent abstinence at 12 months, confirmed by exhaled CO <=10 (NCT02148445)
Timeframe: Month 12
| Intervention | Participants (Count of Participants) |
|---|---|
| Standard Smoking Cessation | 23 |
| Extended Nicotine Replacement Therapy | 24 |
"6 month sustained abstinence as measured by self-report at 6 and 12 months and confirmed by CO at 6 and 12 months. Participants who were confirmed as non-smokers by carbon monoxide (CO) at both Month 6 and Month 12 were considered to have 6-month sustained abstinence." (NCT02148445)
Timeframe: Month 6 through Month 12
| Intervention | Participants (Count of Participants) |
|---|---|
| Standard Smoking Cessation | 15 |
| Extended Nicotine Replacement Therapy | 12 |
"Self-reported and biochemically verified 7-day abstinence. Participants were asked at Month 3, Month 6, and Month 12, Have you smoked any cigarettes or little cigars, even a puff, in the past 7 days? They also completed an exhaled carbon monoxide lab test at Month 3, 6 and 12. Biochemical verification= exhaled CO <=10 ppm. Month 12 biochemically verified abstinence is the primary outcome, and is not reported in this table." (NCT02148445)
Timeframe: Month 3, Month 6, Month 12
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Month 3, self-report | Month 3, biochemically verified | Month 6, self-report | Month 6, biochemically verified | Month 12, self-report | |
| Extended Nicotine Replacement Therapy | 16 | 14 | 20 | 19 | 28 |
| Standard Smoking Cessation | 27 | 25 | 28 | 25 | 25 |
"Average number of cigarettes per day over one year. Participants were asked at Month 3, Month 6, and Month 12 During the past 7 days, on those days that you smoked, what was the average number of cigarettes or little cigars smoked per day?" (NCT02148445)
Timeframe: Month 3, Month 6, Month 12
| Intervention | cigarettes per day (Mean) | ||
|---|---|---|---|
| Month 3 | Month 6 | Month 12 | |
| Extended Nicotine Replacement Therapy | 10.5 | 9.1 | 8.1 |
| Standard Smoking Cessation | 7.9 | 8.1 | 8.5 |
"Average number of cigarettes per day over one year, among continued smokers. All participants were asked During the past 7 days, on those days that you smoked, what was the average number of cigarettes smoked per day? at Month 3, Month 6, and Month 12. This analysis looks at the number of cigarettes per day among participants who were still smoking." (NCT02148445)
Timeframe: Month 3, Month 6, Month 12
| Intervention | cigarettes per day (Mean) | ||
|---|---|---|---|
| Month 3 | Month 6 | Month 12 | |
| Extended Nicotine Replacement Therapy | 11.4 | 9.9 | 9.3 |
| Standard Smoking Cessation | 8.7 | 9.1 | 9.7 |
Carbon monoxide (CO) exposure over 12 months. At Month 3, Month 6, and Month 12, participants completed an expired carbon monoxide laboratory test, which measured CO in parts per million. (NCT02148445)
Timeframe: Month 3, Month 6, Month 12
| Intervention | parts per million (ppm) (Mean) | ||
|---|---|---|---|
| Month 3 | Month 6 | Month 12 | |
| Extended Nicotine Replacement Therapy | 17.4 | 15.4 | 13.8 |
| Standard Smoking Cessation | 15.0 | 14.6 | 15.5 |
Carbon monoxide (CO) exposure over 12 months. At Month 3, Month 6, and Month 12, participants completed an expired carbon monoxide laboratory test, which measured CO in parts per million. This analysis looks at CO among those continuing to smoke. (NCT02148445)
Timeframe: Month 3, Month 6, Month 12
| Intervention | parts per million (ppm) (Mean) | ||
|---|---|---|---|
| Month 3 | Month 6 | Month 12 | |
| Extended Nicotine Replacement Therapy | 18.8 | 17.0 | 15.8 |
| Standard Smoking Cessation | 16.4 | 16.0 | 17.4 |
Creatinine-adjusted NNAL (4-(methylnitrosamino)-1-(3)pyridyl-1-butanol)) exposure over 12 months. At Month 3, Month 6, and Month 12, participants provided a urine sample that was used to assess their level of urinary creatinine and NNAL. (NCT02148445)
Timeframe: Month 3, Month 6, Month 12
| Intervention | pg/mg creatinine (Geometric Mean) | ||
|---|---|---|---|
| Month 3 | Month 6 | Month 12 | |
| Extended Nicotine Replacement Therapy | 320.1 | 186.0 | 183.5 |
| Standard Smoking Cessation | 279.0 | 178.2 | 190.4 |
Creatinine-adjusted NNAL (4-(methylnitrosamino)-1-(3)pyridyl-1-butanol)) exposure over 12 months. At Month 3, Month 6, and Month 12, participants provided a urine sample that was used to assess their level of urinary creatinine and NNAL. This analysis looks at NNAL among continuing smokers only. (NCT02148445)
Timeframe: Month 3, Month 6, Month 12
| Intervention | pg/mg creatinine (Geometric Mean) | ||
|---|---|---|---|
| Month 3 | Month 6 | Month 12 | |
| Extended Nicotine Replacement Therapy | 337.6 | 217.1 | 247.5 |
| Standard Smoking Cessation | 314.6 | 219.8 | 257.0 |
Cotinine over 12 months, adjusted for creatinine. At Month 3, Month 6, and Month 12, participants provided a urine sample that was used to assess their level of urinary creatinine and cotinine. (NCT02148445)
Timeframe: Month 3, Month 6, Month 12
| Intervention | ng/mg creatinine (Geometric Mean) | ||
|---|---|---|---|
| Month 3 | Month 6 | Month 12 | |
| Extended Nicotine Replacement Therapy | 3378.1 | 3342.3 | 2363.7 |
| Standard Smoking Cessation | 2652.5 | 2390.7 | 2159.0 |
Cotinine over 12 months, adjusted for creatinine. At Month 3, Month 6, and Month 12, participants provided a urine sample that was used to assess their level of urinary creatinine and cotinine. This analysis looks at NNAL among continuing smokers only. (NCT02148445)
Timeframe: Month 3, Month 6, Month 12
| Intervention | ng/mg creatinine (Geometric Mean) | ||
|---|---|---|---|
| Month 3 | Month 6 | Month 12 | |
| Extended Nicotine Replacement Therapy | 3305.8 | 3502.2 | 2782.7 |
| Standard Smoking Cessation | 2771.2 | 2850.7 | 2733.9 |
Number of self-reported quit attempts over one year. At Month 3 and Month 6, participants reported the number of quit attempts in the last 3 months. At Month 12, participants reported the number of quit attempts in the last 6 months. (NCT02148445)
Timeframe: Month 3, Month 6, Month 12
| Intervention | number of quit attempts (Mean) | ||
|---|---|---|---|
| Month 3 | Month 6 | Month 12 | |
| Extended Nicotine Replacement Therapy | 3.7 | 4.8 | 6.2 |
| Standard Smoking Cessation | 4.6 | 4.5 | 5.7 |
Respiratory symptoms as measured by the COPD Assessment Test (CAT) respiratory questionnaire. Participants completed this 8-item assessment at Month 3, Month 6, and Month 12. Scores range from 0 to 40, with higher levels indicating higher impact of COPD on well-being and daily life. (NCT02148445)
Timeframe: Month 3, Month 6, Month 12
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Month 3 | Month 6 | Month 12 | |
| Extended Nicotine Replacement Therapy | 19.3 | 18.1 | 18.2 |
| Standard Smoking Cessation | 17.8 | 17.9 | 17.5 |
Number of cardiac-related hospital admissions and emergency room visits. Participants were asked how many times they had visited the ED or were admitted to the hospital for cardiac-related problems at Month 3, Month 6, and Month 12. (NCT02148445)
Timeframe: Month 3, Month 6, Month 12
| Intervention | Participants (Count of Participants) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Month 371962791 | Month 371962792 | Month 671962791 | Month 671962792 | Month 1271962791 | Month 1271962792 | |||||||||||||
| 0 Visits | 2 or more Visits | 1 Visit | ||||||||||||||||
| Standard Smoking Cessation | 181 | |||||||||||||||||
| Extended Nicotine Replacement Therapy | 185 | |||||||||||||||||
| Standard Smoking Cessation | 7 | |||||||||||||||||
| Extended Nicotine Replacement Therapy | 6 | |||||||||||||||||
| Standard Smoking Cessation | 1 | |||||||||||||||||
| Extended Nicotine Replacement Therapy | 0 | |||||||||||||||||
| Standard Smoking Cessation | 171 | |||||||||||||||||
| Extended Nicotine Replacement Therapy | 180 | |||||||||||||||||
| Standard Smoking Cessation | 10 | |||||||||||||||||
| Extended Nicotine Replacement Therapy | 4 | |||||||||||||||||
| Standard Smoking Cessation | 0 | |||||||||||||||||
| Extended Nicotine Replacement Therapy | 1 | |||||||||||||||||
| Standard Smoking Cessation | 175 | |||||||||||||||||
| Extended Nicotine Replacement Therapy | 167 | |||||||||||||||||
| Standard Smoking Cessation | 8 | |||||||||||||||||
| Extended Nicotine Replacement Therapy | 12 | |||||||||||||||||
| Standard Smoking Cessation | 2 | |||||||||||||||||
| Extended Nicotine Replacement Therapy | 3 | |||||||||||||||||
Number of respiratory-related hospital admissions and emergency room visits. Participants were asked how many times they had visited the ED or were admitted to the hospital for respiratory-related problems at Month 3, Month 6, and Month 12 (NCT02148445)
Timeframe: Month 3, Month 6, Month 12
| Intervention | Participants (Count of Participants) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Month 371962791 | Month 371962792 | Month 671962792 | Month 671962791 | Month 1271962791 | Month 1271962792 | |||||||||||||
| 0 Visits | 1 Visit | 2 or more Visits | ||||||||||||||||
| Standard Smoking Cessation | 176 | |||||||||||||||||
| Extended Nicotine Replacement Therapy | 169 | |||||||||||||||||
| Standard Smoking Cessation | 11 | |||||||||||||||||
| Extended Nicotine Replacement Therapy | 15 | |||||||||||||||||
| Standard Smoking Cessation | 2 | |||||||||||||||||
| Standard Smoking Cessation | 152 | |||||||||||||||||
| Extended Nicotine Replacement Therapy | 154 | |||||||||||||||||
| Standard Smoking Cessation | 22 | |||||||||||||||||
| Extended Nicotine Replacement Therapy | 24 | |||||||||||||||||
| Standard Smoking Cessation | 7 | |||||||||||||||||
| Extended Nicotine Replacement Therapy | 7 | |||||||||||||||||
| Standard Smoking Cessation | 157 | |||||||||||||||||
| Extended Nicotine Replacement Therapy | 153 | |||||||||||||||||
| Standard Smoking Cessation | 18 | |||||||||||||||||
| Extended Nicotine Replacement Therapy | 20 | |||||||||||||||||
| Standard Smoking Cessation | 10 | |||||||||||||||||
| Extended Nicotine Replacement Therapy | 10 | |||||||||||||||||
Imaging of the whole lung (WL) is performed using a volumetric high resolution computerized tomography (HRCT) scan, which is then analyzed using a computer algorithm to determine the percentage of overall pixels exhibiting features characteristic for quantitative lung fibrosis (QLF). Higher percentages for QLF-WL therefore represent greater involvement by lung fibrosis. (NCT00883129)
Timeframe: Measured at baseline and Month 24
| Intervention | % of lung exhibiting QLF (Mean) | |
|---|---|---|
| Baseline | Month 24 | |
| Cyclophosphamide Arm | 8.91 | 8.48 |
| Mycophenolate Arm | 8.25 | 7.99 |
The primary outcome is the course over time from baseline to 24 months for the FVC %-predicted. The FVC %-predicted represents the adjusted volume of air (adjusted as a percentage of the expected normal valued based on the participant's age, height, gender and ethnicity) that can be forcibly exhaled from the lungs after taking the deepest breath possible. The FVC %-predicted is reduced in patients with interstitial lung disease and is used as a measure of lung involvement and disease severity. (NCT00883129)
Timeframe: Measured at study Baseline and Months 3, 6, 12, 15, 18, 21, and 24
| Intervention | FVC %-pred (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | Month 3 | Month 6 | Month 9 | Month 12 | Month 15 | Month 18 | Month 21 | Month 24 | |
| Cyclophosphamide Arm | 66.52 | 67.03 | 67.86 | 69.42 | 69.86 | 71.94 | 72.57 | 72.55 | 70.15 |
| Mycophenolate Arm | 66.52 | 66.22 | 68.02 | 68.11 | 68.43 | 69.84 | 70.57 | 70.87 | 69.65 |
The HAQ-DI asks questions related to 8 activity domains (dressing, arising, eating, walking, hygiene, reach, grip, and common daily activities) with the patient's capacity to carry out each activity scored from 0 to 3. Scores across all domains are averaged and a higher score represents greater disability. (NCT00883129)
Timeframe: Measured at study entry and Months 3, 6, 9, 12, 15, 18, 21, and 24
| Intervention | HAQ-DI Total Score (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | Month 3 | Month 6 | Month 9 | Month 12 | Month 15 | Month 18 | Month 21 | Month 24 | |
| Cyclophosphamide Arm | 0.74 | 0.64 | 0.58 | 0.65 | 0.56 | 0.62 | 0.55 | 0.48 | 0.57 |
| Mycophenolate Arm | 0.71 | 0.83 | 0.75 | 0.66 | 0.64 | 0.58 | 0.55 | 0.65 | 0.62 |
The DLCO is a pulmonary function test that measures the capacity for the lung to carry out gas exchange between the inhaled breath and the pulmonary capillary blood vessels and the DLCO %-predicted represents the DLCO expressed as a percentage of the expected normal valued based on the participant's age, height, gender and ethnicity. The DLCO %-predicted is reduced in patients with interstitial lung disease and is used as a measure of disease severity. (NCT00883129)
Timeframe: Measured at study entry and Months 3, 6, 12, 15, 18, 21, and 24
| Intervention | DLCO %-pred (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | Month 3 | Month 6 | Month 9 | Month 12 | Month 15 | Month 18 | Month 21 | Month 24 | |
| Cyclophosphamide Arm | 54.05 | 51.92 | 50.87 | 51.55 | 53.12 | 53.62 | 55.9 | 54.26 | 52.90 |
| Mycophenolate Arm | 53.99 | 53.38 | 54.86 | 54.13 | 55.32 | 57.77 | 56.62 | 55.47 | 55.31 |
Skin thickness is quantified using the modified Rodnan measurement method (mRSS), with a scale that ranges from 0 (no skin involvement) to a maximum of 51. The reported skin score is determined by a clinical assessment of skin thickness, which is performed by a trained reader, and represents the sum of individual assessments that are made in each of 17 body areas. Each area is given a score in the range of 0-3 (0 = normal; 1= mild thickness; 2 = moderate; 3 = severe thickness). A higher score represents more severe skin involvement. (NCT00883129)
Timeframe: Measured at baseline and Months 3, 6, 9, 12, 15, 18, 21, and 24
| Intervention | mRSS score (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | Month 3 | Month 6 | Month 9 | Month 12 | Month 15 | Month 18 | Month 21 | Month 24 | |
| Cyclophosphamide Arm | 14.04 | 12.85 | 11.95 | 10.61 | 9.47 | 9.80 | 9.87 | 8.50 | 7.87 |
| Mycophenolate Arm | 15.32 | 16.03 | 14.37 | 14.33 | 12.45 | 12.43 | 11.98 | 11.22 | 11.40 |
The number of participants who remained in the study at the listed time points are reported (NCT00883129)
Timeframe: Continuous assessment from randomization to 24 months
| Intervention | Participants (Count of Participants) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | Month 3 | Month 6 | Month 9 | Month 12 | Month 15 | Month 18 | Month 21 | Month 24 | |
| Cyclophosphamide Arm | 73 | 64 | 56 | 51 | 46 | 44 | 42 | 39 | 38 |
| Mycophenolate Arm | 69 | 66 | 58 | 55 | 52 | 52 | 49 | 49 | 49 |
The TLC represents the total volume of air within the lung after taking the deepest breath possible and the TLC %-predicted represents the TLC expressed as a percentage of the expected normal valued based on the participant's age, height, gender and ethnicity. The TLC %-predicted is reduced in patients with interstitial lung disease and is used as a measure of disease severity. (NCT00883129)
Timeframe: Measured at study entry and Months 6, 12, 18, and 24
| Intervention | TLC %-pred (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Month 6 | Month 12 | Month 18 | Month 24 | |
| Cyclophosphamide Arm | 65.49 | 67.39 | 68.25 | 69.63 | 66.97 |
| Mycophenolate Arm | 66.16 | 67.84 | 67.31 | 68.50 | 68.24 |
(NCT00883129)
Timeframe: Measured throughout the 2-year study
| Intervention | Participants (Count of Participants) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Leukopenia (<2.5x10^3 WBC/microliter) | Neutropenia (<1.0x10^3 neutrophils/microliter) | Anemia (Hgb <10 g/dl) | Thrombocytopenia (<100x10^3 platelets/microliter) | Hematuria (>10 RBC/high power field) | Pneumonia | SAE-Total | SAE-related to treatment | Deaths | |
| Cyclophosphamide Arm | 30 | 7 | 13 | 4 | 2 | 4 | 22 | 7 | 11 |
| Mycophenolate Arm | 4 | 3 | 8 | 0 | 3 | 5 | 27 | 3 | 5 |
Change in breathlessness was assessed using the Transitional Dyspnea Index, which compares current symptoms to those at baseline. Total score ranges from - 9 to + 9. The lower the score, the more deterioration in severity of dyspnea. (NCT00883129)
Timeframe: Measured at Months 6, 12, 18, and 24
| Intervention | Transitional Dyspnea Index Score (Mean) | |||
|---|---|---|---|---|
| Month 6 | Month 12 | Month 18 | Month 24 | |
| Cyclophosphamide Arm | 0.31 | 1.23 | 1.78 | 2.09 |
| Mycophenolate Arm | 0.74 | 1.17 | 0.91 | 1.86 |
Participants with progressive disease at baseline with decline in FEV1 greater than 10% (NCT01287078)
Timeframe: 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Inhaled Cyclosporine in HSCT Recipients | 2 |
| Inhaled Cyclosporine in Lung Transplant Recipients | 0 |
Participants with progressive disease at baseline with stablization of FEV1 (NCT01287078)
Timeframe: 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Inhaled Cyclosporine in HSCT Recipients | 2 |
| Inhaled Cyclosporine in Lung Transplant Recipients | 0 |
Participants with stable disease at baseline with stablization in FEV1 and greater than 25% decline in systemic immunosuppression (NCT01287078)
Timeframe: 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Inhaled Cyclosporine in HSCT Recipients | 3 |
| Inhaled Cyclosporine in Lung Transplant Recipients | 0 |
Participants who did not respond to treatment with cyclosporine inhalation solution (CIS) (NCT01287078)
Timeframe: 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Inhaled Cyclosporine in HSCT Recipients | 7 |
| Inhaled Cyclosporine in Lung Transplant Recipients | 2 |
Participants who responded to treatment with cyclosporine inhalation solution (CIS) (NCT01287078)
Timeframe: 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Inhaled Cyclosporine in HSCT Recipients | 9 |
| Inhaled Cyclosporine in Lung Transplant Recipients | 0 |
Participants with stable disease at baseline with stablization of FEV1 and no change or increase in systemic immunosuppresion (NCT01287078)
Timeframe: 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Inhaled Cyclosporine in HSCT Recipients | 4 |
| Inhaled Cyclosporine in Lung Transplant Recipients | 2 |
Participants with stable or progressive disease at baseline with greater than 20% of decline in FEV1 (NCT01287078)
Timeframe: 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Inhaled Cyclosporine in HSCT Recipients | 1 |
| Inhaled Cyclosporine in Lung Transplant Recipients | 0 |
Participants with stable or progressive disease at baseline with improvement of FEV1 (NCT01287078)
Timeframe: 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Inhaled Cyclosporine in HSCT Recipients | 4 |
| Inhaled Cyclosporine in Lung Transplant Recipients | 0 |
34 reviews available for carbon monoxide and Lung Diseases
| Article | Year |
|---|---|
Recent advances in HIV-associated chronic lung disease clinical research.
Topics: Carbon Monoxide; HIV Infections; HIV-1; Humans; Lung; Lung Diseases; Pulmonary Disease, Chronic Obst | 2021 |
The Use of Hemoglobin Vesicles for Delivering Medicinal Gas for the Treatment of Intractable Disorders.
Topics: Animals; Biomimetics; Blood Substitutes; Carbon Monoxide; Colitis; Hemoglobins; Humans; Lung Disease | 2017 |
Carbon monoxide in lung cell physiology and disease.
Topics: Animals; Carbon Monoxide; Dose-Response Relationship, Drug; Humans; Lung; Lung Diseases; Mitochondri | 2018 |
Simultaneous measurement of pulmonary diffusing capacity for carbon monoxide and nitric oxide.
Topics: Blood Volume; Carbon Monoxide; Hemoglobins; Humans; Japan; Lung Diseases; Microcirculation; Nitric O | 2018 |
[New era of laboratory testing. Topics: II. Particulars; 9. The recent advances of pulmonary function tests].
Topics: Biomarkers; Carbon Monoxide; Humans; Lung; Lung Diseases; Nitrogen Oxides; Respiratory Function Test | 2013 |
Carbon monoxide: endogenous mediator, potential diagnostic and therapeutic target.
Topics: Animals; Biomarkers; Carbon Monoxide; Cardiovascular Diseases; Exhalation; Gene Expression; Heme Oxy | 2010 |
Exhaled carbon monoxide in airway diseases: from research findings to clinical relevance.
Topics: Biomarkers; Breath Tests; Carbon Monoxide; Exhalation; Heme Oxygenase-1; Humans; Lung Diseases; Nitr | 2010 |
Update in environmental and occupational medicine 2010.
Topics: Air Pollution; Asthma; Biomass; Carbon Monoxide; Cardiovascular Diseases; Humans; Lung Diseases; Occ | 2011 |
Examination of the carbon monoxide diffusing capacity (DL(CO)) in relation to its KCO and VA components.
Topics: Carbon Monoxide; Exercise; Humans; Lung; Lung Diseases; Lung Volume Measurements; Pulmonary Alveoli; | 2012 |
Breath biomarkers in diagnosis of pulmonary diseases.
Topics: Asthma; Biomarkers; Breath Tests; Carbon Monoxide; Cystic Fibrosis; Humans; Hydrogen Peroxide; Lung | 2012 |
The TL,NO/TL,CO ratio in pulmonary function test interpretation.
Topics: Blood Gas Analysis; Carbon Monoxide; Exercise; Humans; Lung Diseases; Nitric Oxide; Pulmonary Diffus | 2013 |
Heme oxygenase-1 and carbon monoxide in pulmonary medicine.
Topics: Animals; Carbon Monoxide; Heme Oxygenase-1; Humans; Lung Diseases; Pneumonia | 2003 |
Air pollution and cardiovascular disease: a statement for healthcare professionals from the Expert Panel on Population and Prevention Science of the American Heart Association.
Topics: Air Pollutants; Air Pollution; Carbon Monoxide; Cardiovascular Diseases; Disease Susceptibility; Epi | 2004 |
Air pollution and cardiovascular disease: a statement for healthcare professionals from the Expert Panel on Population and Prevention Science of the American Heart Association.
Topics: Air Pollutants; Air Pollution; Carbon Monoxide; Cardiovascular Diseases; Disease Susceptibility; Epi | 2004 |
Air pollution and cardiovascular disease: a statement for healthcare professionals from the Expert Panel on Population and Prevention Science of the American Heart Association.
Topics: Air Pollutants; Air Pollution; Carbon Monoxide; Cardiovascular Diseases; Disease Susceptibility; Epi | 2004 |
Air pollution and cardiovascular disease: a statement for healthcare professionals from the Expert Panel on Population and Prevention Science of the American Heart Association.
Topics: Air Pollutants; Air Pollution; Carbon Monoxide; Cardiovascular Diseases; Disease Susceptibility; Epi | 2004 |
Exhaled breath measures of inflammation: are they useful in neonatal chronic lung disease?
Topics: Biomarkers; Breath Tests; Carbon Monoxide; Chronic Disease; Humans; Hydrocarbons; Infant, Newborn; I | 2005 |
Heme oxygenase-1: from bench to bedside.
Topics: Animals; Bilirubin; Carbon Monoxide; Diffusion of Innovation; Heme Oxygenase (Decyclizing); Heme Oxy | 2005 |
Carbon monoxide and bilirubin: potential therapies for pulmonary/vascular injury and disease.
Topics: Animals; Bilirubin; Carbon Monoxide; Humans; Lung Diseases; Oxidative Stress; Reperfusion Injury; Va | 2007 |
Cytoprotective and anti-inflammatory actions of carbon monoxide in organ injury and sepsis models.
Topics: Animals; Anti-Inflammatory Agents; Carbon Monoxide; Humans; Lung Diseases; Oxidative Stress; Reperfu | 2007 |
Carbon monoxide in sepsis.
Topics: Anti-Inflammatory Agents; Apoptosis; Carbon Monoxide; Dose-Response Relationship, Drug; Forecasting; | 2007 |
Protective functions of heme oxygenase-1 and carbon monoxide in the respiratory system.
Topics: Animals; Carbon Monoxide; Heme Oxygenase-1; Humans; Lung Diseases; Models, Biological; Protective Ag | 2007 |
Carbon monoxide: medicinal chemistry and biological effects.
Topics: Animals; Anti-Inflammatory Agents; Carbon Monoxide; Graft Rejection; Graft Survival; Heart Transplan | 2007 |
Impact of air quality in exercise performance.
Topics: Adult; Air Pollution; Asbestos; Carbon Monoxide; Cardiovascular Diseases; Environmental Pollutants; | 1981 |
Measurements of pulmonary epithelial permeability in vivo.
Topics: Aerosols; Biological Transport, Active; Capillary Permeability; Carbon Monoxide; Cell Membrane Perme | 1983 |
The health risks of passive smoking. The growing case for control measures in enclosed environments.
Topics: Adult; Carbon Monoxide; Cardiovascular Diseases; Child; Child, Preschool; Female; Humans; Legislatio | 1983 |
The experimental pathology of oxidant and air pollutant inhalation.
Topics: Adolescent; Adult; Aged; Air Pollutants; Animals; Carbon Monoxide; Female; Haplorhini; Humans; Lung | 1980 |
[The measurement of pulmonary diffusing capacity for carbon monoxide].
Topics: Capillaries; Carbon Monoxide; Female; Humans; Lung; Lung Diseases; Male; Pulmonary Diffusing Capacit | 1997 |
Gas analysis.
Topics: Adult; Age Factors; Asthma; Biomarkers; Breath Tests; Carbon Monoxide; Child; Cystic Fibrosis; Elect | 2000 |
Indoor air pollution in developing countries: a major environmental and public health challenge.
Topics: Adult; Air Pollution, Indoor; Carbon Monoxide; Child; Developing Countries; Female; Heating; Humans; | 2000 |
Indoor air pollution in developing countries: a major environmental and public health challenge.
Topics: Adult; Air Pollution, Indoor; Carbon Monoxide; Child; Developing Countries; Female; Heating; Humans; | 2000 |
Indoor air pollution in developing countries: a major environmental and public health challenge.
Topics: Adult; Air Pollution, Indoor; Carbon Monoxide; Child; Developing Countries; Female; Heating; Humans; | 2000 |
Indoor air pollution in developing countries: a major environmental and public health challenge.
Topics: Adult; Air Pollution, Indoor; Carbon Monoxide; Child; Developing Countries; Female; Heating; Humans; | 2000 |
Indoor air pollution in developing countries: a major environmental and public health challenge.
Topics: Adult; Air Pollution, Indoor; Carbon Monoxide; Child; Developing Countries; Female; Heating; Humans; | 2000 |
Indoor air pollution in developing countries: a major environmental and public health challenge.
Topics: Adult; Air Pollution, Indoor; Carbon Monoxide; Child; Developing Countries; Female; Heating; Humans; | 2000 |
Indoor air pollution in developing countries: a major environmental and public health challenge.
Topics: Adult; Air Pollution, Indoor; Carbon Monoxide; Child; Developing Countries; Female; Heating; Humans; | 2000 |
Indoor air pollution in developing countries: a major environmental and public health challenge.
Topics: Adult; Air Pollution, Indoor; Carbon Monoxide; Child; Developing Countries; Female; Heating; Humans; | 2000 |
Indoor air pollution in developing countries: a major environmental and public health challenge.
Topics: Adult; Air Pollution, Indoor; Carbon Monoxide; Child; Developing Countries; Female; Heating; Humans; | 2000 |
Indoor air pollution in developing countries: a major environmental and public health challenge.
Topics: Adult; Air Pollution, Indoor; Carbon Monoxide; Child; Developing Countries; Female; Heating; Humans; | 2000 |
Indoor air pollution in developing countries: a major environmental and public health challenge.
Topics: Adult; Air Pollution, Indoor; Carbon Monoxide; Child; Developing Countries; Female; Heating; Humans; | 2000 |
Indoor air pollution in developing countries: a major environmental and public health challenge.
Topics: Adult; Air Pollution, Indoor; Carbon Monoxide; Child; Developing Countries; Female; Heating; Humans; | 2000 |
Indoor air pollution in developing countries: a major environmental and public health challenge.
Topics: Adult; Air Pollution, Indoor; Carbon Monoxide; Child; Developing Countries; Female; Heating; Humans; | 2000 |
Indoor air pollution in developing countries: a major environmental and public health challenge.
Topics: Adult; Air Pollution, Indoor; Carbon Monoxide; Child; Developing Countries; Female; Heating; Humans; | 2000 |
Indoor air pollution in developing countries: a major environmental and public health challenge.
Topics: Adult; Air Pollution, Indoor; Carbon Monoxide; Child; Developing Countries; Female; Heating; Humans; | 2000 |
Indoor air pollution in developing countries: a major environmental and public health challenge.
Topics: Adult; Air Pollution, Indoor; Carbon Monoxide; Child; Developing Countries; Female; Heating; Humans; | 2000 |
Exhaled markers of pulmonary disease.
Topics: Biomarkers; Breath Tests; Carbon Monoxide; Humans; Hydrocarbons; Lung Diseases; Nitric Oxide | 2001 |
Exhaled monoxides as a pulmonary function test: use of exhaled nitric oxide and carbon monoxide.
Topics: Breath Tests; Carbon Monoxide; Humans; Lung Diseases; Nitric Oxide; Respiration; Respiratory Functio | 2001 |
The filter cigarette controversy.
Topics: Animals; Carbon Monoxide; Filtration; Humans; Lung Diseases; Safety; Smoking | 1979 |
Indoor air pollutants. A literature review.
Topics: Air Pollution, Indoor; Asbestos; Asphyxia; Carbon Monoxide; Cardiovascular Diseases; Formaldehyde; H | 1991 |
[Medico-social aspects of air pollution].
Topics: Air Pollution; Asthma; Benzopyrenes; Bronchitis; Carbon Dioxide; Carbon Monoxide; Dust; Environmenta | 1971 |
Pulmonary effects of air pollution.
Topics: Air Pollution; Animals; Carbon Monoxide; Drug Synergism; Female; Humans; Lung Diseases; Male; Nitrog | 1969 |
Studies of pulmonary and cardiac function using short-lived isotopes oxygen-15, nitrogen-13 and carbon-11.
Topics: Blood Volume Determination; Carbon Dioxide; Carbon Isotopes; Carbon Monoxide; Half-Life; Heart Disea | 1968 |
7 trials available for carbon monoxide and Lung Diseases
| Article | Year |
|---|---|
Effect of Long-term Nicotine Replacement Therapy vs Standard Smoking Cessation for Smokers With Chronic Lung Disease: A Randomized Clinical Trial.
Topics: Adult; Aged; Carbon Monoxide; Chronic Disease; Counseling; Female; Humans; Lung Diseases; Male; Midd | 2018 |
Feasibility intervention trial of two types of improved cookstoves in three resource-limited settings: study protocol for a randomized controlled trial.
Topics: Adult; Air Pollutants; Air Pollution, Indoor; Blood Pressure; Carbon Monoxide; Cooking; Cross-Over S | 2013 |
Does lung diffusion impairment affect exercise capacity in patients with heart failure?
Topics: Blood Gas Analysis; Carbon Monoxide; Cardiac Output, Low; Chronic Disease; Exercise Test; Exercise T | 2002 |
Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study.
Topics: Carbon Monoxide; Double-Blind Method; Dyspnea; Female; Health Status; Humans; Lung Diseases; Male; M | 2005 |
Measurement of transfer factor during constant exhalation.
Topics: Adult; Aged; Carbon Monoxide; Female; Forced Expiratory Volume; Humans; Lung Diseases; Male; Middle | 1994 |
Relating radiation-induced regional lung injury to changes in pulmonary function tests.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Carbon Monoxide; Dose-Response Relationship, Radia | 2001 |
Corticosteroid therapy of pulmonary sarcoidosis. A prospective evaluation of alternate day and daily dosage in stage II disease.
Topics: Carbon Monoxide; Female; Follow-Up Studies; Forced Expiratory Volume; Humans; Lung Diseases; Male; M | 1979 |
186 other studies available for carbon monoxide and Lung Diseases
| Article | Year |
|---|---|
Pulmonary Outcomes After Autologous Stem Cell Transplant for Hodgkin Lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carbon Monoxide; Child; Hematopoietic Stem Cell Tran | 2022 |
Isolated abnormal diffusing capacity for carbon monoxide (iso↓DLco) is associated with increased respiratory symptom burden in people with HIV infection.
Topics: Asthma; Carbon Monoxide; Cross-Sectional Studies; Forced Expiratory Volume; HIV Infections; Humans; | 2023 |
Lung health and exposure to air pollution in Malawian children (CAPS): a cross-sectional study.
Topics: Air Pollution, Indoor; Body Height; Body Weight; Carbon Monoxide; Carboxyhemoglobin; Child; Chronic | 2019 |
The protective effects of thymoquinone on lung damage caused by cigarette smoke.
Topics: Animals; Benzoquinones; Carbon Monoxide; Cytokines; Gene Expression Regulation; Lung Diseases; Male; | 2020 |
Association Between Inflammatory Pathways and Phenotypes of Pulmonary Dysfunction Using Cluster Analysis in Persons Living With HIV and HIV-Uninfected Individuals.
Topics: Adult; Carbon Monoxide; CD4 Lymphocyte Count; Cluster Analysis; Cohort Studies; Female; HIV Infectio | 2020 |
Lung function in men with and without HIV.
Topics: Adult; Aged; Carbon Monoxide; Cross-Sectional Studies; Female; Forced Expiratory Volume; HIV Infecti | 2020 |
Diffuse alveolar hemorrhage secondary to plastic fume exposure: A case report.
Topics: Adult; Bronchoscopy; Carbon Monoxide; Cough; Hemoptysis; Hemorrhage; Humans; Lung Diseases; Male; Oc | 2020 |
Indoor air pollution and its association with poor lung function, microalbuminuria and variations in blood pressure among kitchen workers in India: a cross-sectional study.
Topics: Adolescent; Adult; Air Pollutants, Occupational; Air Pollution, Indoor; Albuminuria; Blood Pressure; | 2017 |
Intensive smoking diminishes the differences in quality of life and exacerbation frequency between the alpha-1-antitrypsin deficiency genotypes PiZZ and PiSZ.
Topics: Adult; Aged; alpha 1-Antitrypsin; alpha 1-Antitrypsin Deficiency; Carbon Monoxide; Disease Progressi | 2017 |
Rising stars of DPLD survival: FVC and exercise desaturation (a single-center study)
Topics: Age Factors; Aged; Blood Pressure; Carbon Monoxide; Connective Tissue Diseases; Exercise; Exercise T | 2018 |
Diffusion capacity of the lung-a disease biomarker linking ventilation and circulation.
Topics: Biomarkers; Carbon Monoxide; Humans; Hypertension, Pulmonary; Lung; Lung Diseases | 2019 |
Influence of Mouth Pressure on Measurement of Diffusing Capacity in the Clinical Pulmonary Function Laboratory.
Topics: Adult; Aged; Asthma; Breath Holding; Carbon Monoxide; Dyspnea; Female; Forced Expiratory Volume; Hum | 2019 |
[Pulmonary CO/NO transfer: physiological basis, technical aspects and clinical impact].
Topics: Carbon Monoxide; Erythrocytes; Humans; Lung; Lung Diseases; Nitric Oxide; Pulmonary Diffusing Capaci | 2014 |
Short-term effects of fine particulate air pollution on hospital admissions for respiratory diseases: a case-crossover study in a tropical city.
Topics: Air Pollution; Carbon Monoxide; Cities; Cross-Over Studies; Hospitalization; Humans; Logistic Models | 2014 |
Prevalence and evolution of scleroderma pattern at nailfold videocapillaroscopy in systemic sclerosis patients: Clinical and prognostic implications.
Topics: Adult; Aged; Autoantibodies; Capillaries; Carbon Monoxide; Diffusion; Female; Fingers; Follow-Up Stu | 2015 |
Coarse Particulate Air Pollution Associated with Increased Risk of Hospital Admissions for Respiratory Diseases in a Tropical City, Kaohsiung, Taiwan.
Topics: Air Pollution; Asthma; Carbon Monoxide; Cities; Cross-Over Studies; Hospitalization; Humans; Lung Di | 2015 |
Preclinical lung disease in early rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Bronchiectasis; Carbon Monoxide; Female; Humans; Lung; Lung Diseases; Prospec | 2016 |
Subclinical pulmonary abnormalities in childhood-onset systemic lupus erythematosus patients.
Topics: Adolescent; Age of Onset; Carbon Monoxide; Child; Female; Hospitalization; Humans; Lung Diseases; Lu | 2016 |
Effect of rituximab on pulmonary function in patients with rheumatoid arthritis.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Carbon Monoxide; Female; Follow-Up Studies; Human | 2016 |
A new approach to detect early lung functional impairment in very light smokers.
Topics: Adult; Carbon Monoxide; Exercise; Exercise Test; Female; Humans; Lung; Lung Diseases; Male; Plethysm | 2016 |
Household Air Pollution Intervention Implications: Findings from Qualitative Studies and a Field Trial of Clean Cookstoves in Two Rural Villages in India.
Topics: Air Pollution, Indoor; Carbon Monoxide; Cooking; Environmental Exposure; Environmental Monitoring; F | 2016 |
Pulmonary dysfunction in thalassaemia major: is there any relationship with body iron stores?
Topics: Adult; beta-Thalassemia; Carbon Monoxide; Female; Ferritins; Humans; Iron; Iron Overload; Lung Disea | 2017 |
Can the measurement of pulmonary diffusing capacity for nitric oxide replace the measurement of pulmonary diffusing capacity for carbon monoxide?
Topics: Animals; Carbon Monoxide; Carboxyhemoglobin; Heart Diseases; Hemoglobins; Humans; Lung Diseases; Lun | 2017 |
Executive Summary: 2017 ERS/ATS standards for single-breath carbon monoxide uptake in the lung.
Topics: Breath Tests; Carbon Monoxide; Europe; Humans; Lung Diseases; Practice Guidelines as Topic; Respirat | 2017 |
Clinical measurements of membrane diffusing capacity and pulmonary capillary blood volume.
Topics: Biomarkers; Blood Volume; Capillaries; Carbon Monoxide; Diagnostic Tests, Routine; Humans; Lung; Lun | 2008 |
The carbon monoxide diffusing capacity: clinical implications, coding, and documentation.
Topics: Biomarkers; Capillaries; Carbon Monoxide; Diagnostic Tests, Routine; Humans; Lung; Lung Diseases; Me | 2008 |
Lung hyperinflation: foe or friend?
Topics: Adult; Airway Resistance; Carbon Monoxide; Diving; Humans; Lung; Lung Diseases; Magnetic Resonance I | 2008 |
Carbon monoxide poisoning, or carbon monoxide protection?
Topics: Carbon Monoxide; Carbon Monoxide Poisoning; Continuous Positive Airway Pressure; Heme Oxygenase (Dec | 2008 |
Pulmonary interstitial and vascular abnormalities following cardiac transplantation.
Topics: Capillaries; Carbon Monoxide; Heart Transplantation; Humans; Lung; Lung Diseases; Postoperative Comp | 2008 |
Impact of organic solvents and environmental pollutants on the physiological function in petrol filling workers.
Topics: Adult; Air Pollutants; Benzene; Carbon Monoxide; Control Groups; Humans; India; Industry; Lung; Lung | 2008 |
Exhaled carbon monoxide as a noninvasive marker of airway neutrophilia after lung transplantation.
Topics: Adult; Airway Obstruction; Bronchiolitis Obliterans; Bronchoalveolar Lavage Fluid; C-Reactive Protei | 2009 |
Role of heme oxygenase-1/carbon monoxide system in pulmonary ischemia-reperfusion injury.
Topics: Animals; Carbon Monoxide; Carboxyhemoglobin; Disease Models, Animal; Enzyme Inhibitors; Female; Heme | 2009 |
A clinical prediction rule for pulmonary complications after thoracic surgery for primary lung cancer.
Topics: Aged; Anaerobic Threshold; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Car | 2010 |
Ambient air pollution and daily mortality in Anshan, China: a time-stratified case-crossover analysis.
Topics: Adolescent; Adult; Aged; Air Pollutants; Air Pollution; Carbon Monoxide; Cardiovascular Diseases; Ch | 2010 |
Evaluation of the functional parameters in scleroderma cases with pulmonary involvement.
Topics: Blood Gas Analysis; Carbon Monoxide; Echocardiography; Exercise Tolerance; Female; Humans; Lung Dise | 2010 |
Special issue on carbon monoxide and exhaled biomarkers in human disease.
Topics: Biomarkers; Breath Tests; Carbon Monoxide; Carboxyhemoglobin; Exhalation; Humans; Lung Diseases | 2010 |
[Pulmonary manifestations of polyvinyl chloride exposure].
Topics: Adult; Carbon Monoxide; Cough; Diffusion; Dust; Dyspnea; Female; Humans; Incidence; Lung Diseases; M | 2011 |
Validation of lung function prediction equations from patient survival data.
Topics: Adult; Aged; Carbon Monoxide; Cause of Death; Female; Humans; Lung; Lung Diseases; Male; Middle Aged | 2012 |
Carbon monoxide--a toxic gas on the edge to clinical application.
Topics: Anti-Bacterial Agents; Bacterial Infections; Carbon Monoxide; Humans; Lung Diseases; Protective Agen | 2012 |
Exhaled breath condensate (EBC) biomarkers in pulmonary fibrosis.
Topics: Biomarkers; Breath Tests; Carbon Monoxide; Exhalation; Female; Humans; Hydrogen Peroxide; Lung Disea | 2012 |
Successful treatment of progressive diffuse PEComatosis.
Topics: Adult; Biopsy; Carbon Monoxide; Cell Proliferation; Dyspnea; Female; Genotype; Humans; Lung; Lung Di | 2012 |
Periodontitis is related to lung volumes and airflow limitation: a cross-sectional study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; C-Reactive Protein; Carbon Monoxide; Cross-Sectional St | 2013 |
Exhaled carbon monoxide in lung disease.
Topics: Breath Tests; Carbon Monoxide; Humans; Lung Diseases | 2003 |
Pulmonary side effects of interferon-alpha therapy in patients with hematological malignancies.
Topics: Adult; Aged; Autoimmunity; Carbon Monoxide; Female; Hematologic Neoplasms; Humans; Immunity, Cellula | 2003 |
[The effects of inhaled carbon monoxide on lung injury in rats caused by lipopolysaccharide].
Topics: Acute Disease; Administration, Inhalation; Animals; Bronchoalveolar Lavage Fluid; Carbon Monoxide; D | 2003 |
The lung diffusion coefficient for carbon monoxide in patients with lung disorders, as determined by C14O.
Topics: Carbon Monoxide; Humans; Lung Diseases; Pulmonary Diffusing Capacity; Respiration | 1954 |
Studies on the pulmonary diffusing capacity by the carbon monoxide breath holding technique. II. Patients with various pulmonary diseases.
Topics: Breath Holding; Carbon Monoxide; Humans; Lung Diseases; Pulmonary Diffusing Capacity; Respiration; R | 1961 |
[The pulmonary diffusion of CO in chronic lung diseases].
Topics: Carbon Monoxide; Chronic Disease; Humans; Lung Diseases; Pulmonary Diffusing Capacity; Respiration | 1961 |
D-L-CO measurements with gas chromatography.
Topics: Carbon Monoxide; Chromatography; Chromatography, Gas; Lung; Lung Diseases | 1962 |
[DETERMINATION OF THE DIFFUSION CAPACITY OF THE LUNG WITH AID OF CARBON MONOXIDE (SINGLE RESPIRATION METHOD) IN CHRONIC LUNG DISEASES].
Topics: Carbon Monoxide; Chronic Disease; Humans; Lung Diseases; Pneumonectomy; Respiratory Function Tests | 1964 |
AN ASSESSMENT OF THE FRACTIONAL CARBON MONOXIDE UPTAKE AND ITS RELATIONSHIP TO PULMONARY DIFFUSING CAPACITY.
Topics: Asthma; Carbon Monoxide; Emphysema; Humans; Hyperventilation; Lung Diseases; Physical Exertion; Pulm | 1964 |
DETERMINATION OF THE TRANSFER FACTOR AND HALF TIME OF CARBON MONOXIDE DURING APNEA IN THE HUMAN LUNGS IN NORMAL AND PATHOLOGICAL CASES.
Topics: Apnea; Blood Gas Analysis; Carbon Monoxide; Humans; Lung Diseases; Pathology; Physical Exertion; Pul | 1964 |
THE ACUTE EFFECT OF CIGARETTE SMOKING ON PULMONARY FUNCTION.
Topics: Carbon Monoxide; Humans; Lung; Lung Diseases; Pulmonary Circulation; Respiratory Function Tests; Smo | 1965 |
REDUCTION OF TUMORIGENICITY OF CIGARETTE SMOKE: AN EXPERIMENTAL APPROACH.
Topics: Aldehydes; Animals; Benzopyrenes; Carbon Monoxide; Carcinogens; Cilia; Formates; Lung Diseases; Lung | 1965 |
PULMONARY DIFFUSING CAPACITY FOR CARBON MONOXIDE IN RELATION TO CARDIAC OUTPUT IN MAN.
Topics: Anthropometry; Blood Gas Analysis; Carbon Monoxide; Cardiac Catheterization; Cardiac Output; Contras | 1965 |
THE RELATIONSHIPS BETWEEN MINUTE VENTILATION, PULMONARY GAS DIFFUSION AND RESPIRATORY WORK MEASURED SIMULTANEOUSLY DURING A STANDARD EXERCISE TEST.
Topics: Bronchial Diseases; Bronchiectasis; Bronchitis; Carbon Monoxide; Cystic Fibrosis; Eosinophilic Granu | 1965 |
MKK3 mitogen-activated protein kinase pathway mediates carbon monoxide-induced protection against oxidant-induced lung injury.
Topics: Animals; Carbon Monoxide; Carboxyhemoglobin; Cells, Cultured; Cytokines; Cytoprotection; Enzyme Acti | 2003 |
[Radiological aspects of acute edema of the lungs caused by carbon monoxide poisoning].
Topics: Carbon Monoxide; Carbon Monoxide Poisoning; Edema; Humans; Lung; Lung Diseases; Radiology | 1951 |
Inhaled carbon monoxide confers antiinflammatory effects against ventilator-induced lung injury.
Topics: Administration, Inhalation; Animals; Anti-Inflammatory Agents; Bronchoalveolar Lavage Fluid; Carbon | 2004 |
Transfer factor for carbon monoxide: a glance behind the scene.
Topics: Adult; Aged; Airway Resistance; Carbon Monoxide; Female; Humans; Lung Diseases; Male; Middle Aged; P | 2004 |
Relation of expired carbon monoxide to smoking history, lapsed time, TLCO measurement and passive smoking.
Topics: Adult; Aged; Breath Tests; Carbon Monoxide; Female; Humans; Lung Diseases; Male; Medical History Tak | 2005 |
"Therapeutic" carbon monoxide may be a reality soon.
Topics: Administration, Inhalation; Animals; Anti-Inflammatory Agents; Carbon Monoxide; Disease Models, Anim | 2005 |
"Therapeutic" carbon monoxide may be toxic.
Topics: Administration, Inhalation; Animals; Anti-Inflammatory Agents; Brain Injuries; Carbon Monoxide; Carb | 2005 |
Pattern of diffusion disturbance related to clinical diagnosis: The K(CO) has no diagnostic value next to the DL(CO).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Blood-Air Barrier; Carbon Monoxide; Diffusio | 2006 |
Association of reduced carbon monoxide diffusing capacity with moderate or severe left ventricular diastolic dysfunction in obese persons.
Topics: Adult; Carbon Monoxide; Diastole; Echocardiography, Doppler; Female; Humans; Lung Diseases; Male; Mi | 2005 |
Intrabreath analysis of carbon monoxide uptake during exercise in patients at risk for lung injury.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Breath Tests; Capillaries; Carbon Monoxide; Exercise | 2006 |
Carbon monoxide lung diffusion capacity improves risk stratification in patients without airflow limitation: evidence for systematic measurement before lung resection.
Topics: Aged; Carbon Monoxide; Epidemiologic Methods; Female; Forced Expiratory Volume; Humans; Lung Disease | 2006 |
Carbon monoxide rescues ischemic lungs by interrupting MAPK-driven expression of early growth response 1 gene and its downstream target genes.
Topics: Animals; Carbon Monoxide; Cell Line; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Cyclic GMP; E | 2006 |
Abnormal pulmonary function in adults with sickle cell anemia.
Topics: Acute Disease; Adult; Aged; Anemia, Sickle Cell; Carbon Monoxide; Female; Humans; Logistic Models; L | 2006 |
Carbon monoxide orchestrates a protective response through PPARgamma.
Topics: Animals; Blotting, Western; Carbon Monoxide; Disease Models, Animal; Early Growth Response Protein 1 | 2006 |
Should carbon monoxide lung diffusion capacity (DLCO) measurement be mandatory before lung resection?
Topics: Carbon Monoxide; Humans; Lung Diseases; Pneumonectomy; Preoperative Care; Prognosis; Pulmonary Diffu | 2006 |
Standardisation of lung function testing: helpful guidance from the ATS/ERS Task Force.
Topics: Carbon Monoxide; Humans; Lung Diseases; Lung Volume Measurements; Reference Standards; Spirometry | 2006 |
Standardisation of lung function testing: helpful guidance from the ATS/ERS Task Force.
Topics: Carbon Monoxide; Humans; Lung Diseases; Lung Volume Measurements; Reference Standards; Spirometry | 2006 |
Standardisation of lung function testing: helpful guidance from the ATS/ERS Task Force.
Topics: Carbon Monoxide; Humans; Lung Diseases; Lung Volume Measurements; Reference Standards; Spirometry | 2006 |
Standardisation of lung function testing: helpful guidance from the ATS/ERS Task Force.
Topics: Carbon Monoxide; Humans; Lung Diseases; Lung Volume Measurements; Reference Standards; Spirometry | 2006 |
Standardisation of lung function testing: helpful guidance from the ATS/ERS Task Force.
Topics: Carbon Monoxide; Humans; Lung Diseases; Lung Volume Measurements; Reference Standards; Spirometry | 2006 |
Standardisation of lung function testing: helpful guidance from the ATS/ERS Task Force.
Topics: Carbon Monoxide; Humans; Lung Diseases; Lung Volume Measurements; Reference Standards; Spirometry | 2006 |
Standardisation of lung function testing: helpful guidance from the ATS/ERS Task Force.
Topics: Carbon Monoxide; Humans; Lung Diseases; Lung Volume Measurements; Reference Standards; Spirometry | 2006 |
Standardisation of lung function testing: helpful guidance from the ATS/ERS Task Force.
Topics: Carbon Monoxide; Humans; Lung Diseases; Lung Volume Measurements; Reference Standards; Spirometry | 2006 |
Standardisation of lung function testing: helpful guidance from the ATS/ERS Task Force.
Topics: Carbon Monoxide; Humans; Lung Diseases; Lung Volume Measurements; Reference Standards; Spirometry | 2006 |
Standardisation of lung function testing: helpful guidance from the ATS/ERS Task Force.
Topics: Carbon Monoxide; Humans; Lung Diseases; Lung Volume Measurements; Reference Standards; Spirometry | 2006 |
Standardisation of lung function testing: helpful guidance from the ATS/ERS Task Force.
Topics: Carbon Monoxide; Humans; Lung Diseases; Lung Volume Measurements; Reference Standards; Spirometry | 2006 |
Standardisation of lung function testing: helpful guidance from the ATS/ERS Task Force.
Topics: Carbon Monoxide; Humans; Lung Diseases; Lung Volume Measurements; Reference Standards; Spirometry | 2006 |
Standardisation of lung function testing: helpful guidance from the ATS/ERS Task Force.
Topics: Carbon Monoxide; Humans; Lung Diseases; Lung Volume Measurements; Reference Standards; Spirometry | 2006 |
Standardisation of lung function testing: helpful guidance from the ATS/ERS Task Force.
Topics: Carbon Monoxide; Humans; Lung Diseases; Lung Volume Measurements; Reference Standards; Spirometry | 2006 |
Standardisation of lung function testing: helpful guidance from the ATS/ERS Task Force.
Topics: Carbon Monoxide; Humans; Lung Diseases; Lung Volume Measurements; Reference Standards; Spirometry | 2006 |
Standardisation of lung function testing: helpful guidance from the ATS/ERS Task Force.
Topics: Carbon Monoxide; Humans; Lung Diseases; Lung Volume Measurements; Reference Standards; Spirometry | 2006 |
Standardisation of lung function testing: helpful guidance from the ATS/ERS Task Force.
Topics: Carbon Monoxide; Humans; Lung Diseases; Lung Volume Measurements; Reference Standards; Spirometry | 2006 |
Standardisation of lung function testing: helpful guidance from the ATS/ERS Task Force.
Topics: Carbon Monoxide; Humans; Lung Diseases; Lung Volume Measurements; Reference Standards; Spirometry | 2006 |
Standardisation of lung function testing: helpful guidance from the ATS/ERS Task Force.
Topics: Carbon Monoxide; Humans; Lung Diseases; Lung Volume Measurements; Reference Standards; Spirometry | 2006 |
Standardisation of lung function testing: helpful guidance from the ATS/ERS Task Force.
Topics: Carbon Monoxide; Humans; Lung Diseases; Lung Volume Measurements; Reference Standards; Spirometry | 2006 |
Standardisation of lung function testing: helpful guidance from the ATS/ERS Task Force.
Topics: Carbon Monoxide; Humans; Lung Diseases; Lung Volume Measurements; Reference Standards; Spirometry | 2006 |
Standardisation of lung function testing: helpful guidance from the ATS/ERS Task Force.
Topics: Carbon Monoxide; Humans; Lung Diseases; Lung Volume Measurements; Reference Standards; Spirometry | 2006 |
Standardisation of lung function testing: helpful guidance from the ATS/ERS Task Force.
Topics: Carbon Monoxide; Humans; Lung Diseases; Lung Volume Measurements; Reference Standards; Spirometry | 2006 |
Standardisation of lung function testing: helpful guidance from the ATS/ERS Task Force.
Topics: Carbon Monoxide; Humans; Lung Diseases; Lung Volume Measurements; Reference Standards; Spirometry | 2006 |
Standardisation of lung function testing: helpful guidance from the ATS/ERS Task Force.
Topics: Carbon Monoxide; Humans; Lung Diseases; Lung Volume Measurements; Reference Standards; Spirometry | 2006 |
Standardisation of lung function testing: helpful guidance from the ATS/ERS Task Force.
Topics: Carbon Monoxide; Humans; Lung Diseases; Lung Volume Measurements; Reference Standards; Spirometry | 2006 |
Standardisation of lung function testing: helpful guidance from the ATS/ERS Task Force.
Topics: Carbon Monoxide; Humans; Lung Diseases; Lung Volume Measurements; Reference Standards; Spirometry | 2006 |
Standardisation of lung function testing: helpful guidance from the ATS/ERS Task Force.
Topics: Carbon Monoxide; Humans; Lung Diseases; Lung Volume Measurements; Reference Standards; Spirometry | 2006 |
Standardisation of lung function testing: helpful guidance from the ATS/ERS Task Force.
Topics: Carbon Monoxide; Humans; Lung Diseases; Lung Volume Measurements; Reference Standards; Spirometry | 2006 |
Standardisation of lung function testing: helpful guidance from the ATS/ERS Task Force.
Topics: Carbon Monoxide; Humans; Lung Diseases; Lung Volume Measurements; Reference Standards; Spirometry | 2006 |
Standardisation of lung function testing: helpful guidance from the ATS/ERS Task Force.
Topics: Carbon Monoxide; Humans; Lung Diseases; Lung Volume Measurements; Reference Standards; Spirometry | 2006 |
Standardisation of lung function testing: helpful guidance from the ATS/ERS Task Force.
Topics: Carbon Monoxide; Humans; Lung Diseases; Lung Volume Measurements; Reference Standards; Spirometry | 2006 |
Standardisation of lung function testing: helpful guidance from the ATS/ERS Task Force.
Topics: Carbon Monoxide; Humans; Lung Diseases; Lung Volume Measurements; Reference Standards; Spirometry | 2006 |
Standardisation of lung function testing: helpful guidance from the ATS/ERS Task Force.
Topics: Carbon Monoxide; Humans; Lung Diseases; Lung Volume Measurements; Reference Standards; Spirometry | 2006 |
Standardisation of lung function testing: helpful guidance from the ATS/ERS Task Force.
Topics: Carbon Monoxide; Humans; Lung Diseases; Lung Volume Measurements; Reference Standards; Spirometry | 2006 |
Standardisation of lung function testing: helpful guidance from the ATS/ERS Task Force.
Topics: Carbon Monoxide; Humans; Lung Diseases; Lung Volume Measurements; Reference Standards; Spirometry | 2006 |
End-tidal carbon monoxide measurements in infant respiratory distress syndrome.
Topics: Breath Tests; Carbon Monoxide; Chronic Disease; Humans; Infant, Newborn; Lung Diseases; Prognosis; R | 2006 |
Endothelial STAT3 is essential for the protective effects of HO-1 in oxidant-induced lung injury.
Topics: Animals; Carbon Monoxide; Endothelial Cells; Heme Oxygenase-1; Humans; Hyperoxia; Lung; Lung Disease | 2006 |
Chronic GVHD and pretransplantation abnormalities in pulmonary function are the main determinants predicting worsening pulmonary function in long-term survivors after stem cell transplantation.
Topics: Adolescent; Adult; Carbon Monoxide; Child; Chronic Disease; Comorbidity; Disease Progression; Female | 2006 |
Retrospective study of pulmonary function tests in patients presenting with isolated reduction in single-breath diffusion capacity: implications for the diagnosis of combined obstructive and restrictive lung disease.
Topics: Adult; Aged; Aged, 80 and over; Carbon Monoxide; Dyspnea; Echocardiography; Female; Humans; Lung Dis | 2007 |
Severity of scleroderma lung disease is related to alveolar concentration of nitric oxide.
Topics: Aged; Carbon Monoxide; Echocardiography; Female; Fibrosis; Humans; Lung Diseases; Lung Diseases, Int | 2007 |
The medical consequences of narghile (hookah, shisha) use in the world.
Topics: Carbon Monoxide; Humans; Lung Diseases; Smoking; Tobacco Smoke Pollution | 2007 |
Effects of uneven ventilation-diffusion ratios on pulmonary diffusing capacity in disease.
Topics: Adult; Aged; Blood Gas Analysis; Carbon Monoxide; Female; Humans; Lung; Lung Diseases; Male; Middle | 1967 |
Carbon monoxide diffusing studies in the clinical evaluation of chronic lung diseases.
Topics: Adolescent; Adult; Aged; Blood Gas Analysis; Carbon Dioxide; Carbon Monoxide; Chronic Disease; Femal | 1967 |
[Disturbances in diffusion in chronic pulmonary diseases (Carbon monoxide method)].
Topics: Adolescent; Adult; Aged; Carbon Monoxide; Female; Humans; Lung Diseases; Male; Middle Aged; Pulmonar | 1967 |
[Pathology in firemen].
Topics: Acrolein; Adult; Burns, Inhalation; Carbon Dioxide; Carbon Monoxide; Cardiovascular Diseases; Cyanid | 1983 |
Bleomycin-induced changes in the carbon monoxide transfer factor of the lungs and its components.
Topics: Adult; Bleomycin; Blood Volume; Breath Tests; Capillary Permeability; Carbon Monoxide; Humans; Lung | 1983 |
Arterial oxygenation and pulmonary function with Saralasin in chronic lung disease.
Topics: Adult; Aged; Angiotensin II; Carbon Dioxide; Carbon Monoxide; Cardiac Output; Forced Expiratory Volu | 1983 |
[Regional pulmonary function assessed by C15O2 and 11CO inhalation].
Topics: Carbon Dioxide; Carbon Monoxide; Carbon Radioisotopes; Humans; Lung; Lung Diseases; Pulmonary Circul | 1984 |
Lung transfer factor and KCO at cardiac frequency 100 beats/min as a guide to impaired function of lung parenchyma.
Topics: Adult; Aged; Carbon Monoxide; Female; Heart Rate; Humans; Lung Diseases; Male; Middle Aged; Physical | 1984 |
Tobacco smoke in the workplace: an occupational health hazard.
Topics: Acrolein; Carbon Monoxide; Formaldehyde; Humans; Lung Diseases; Risk; Smoke; Tobacco Smoke Pollution | 1984 |
Noninvasive diagnosis of pulmonary hemorrhage in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Carbon Monoxide; Child; Echocardiography; Female; Heart Atria; Hemorrhage; Hu | 1983 |
Epidemiological study of the lung function of workers at a factory manufacturing polyvinylchloride.
Topics: Adult; Carbon Monoxide; Chemical Industry; Forced Expiratory Volume; Humans; Lung; Lung Diseases; Ma | 1984 |
The single-breath carbon monoxide transfer test 25 years on: a reappraisal. 1--Physiological considerations.
Topics: Carbon Monoxide; Humans; Lung Diseases; Lung Volume Measurements; Pulmonary Alveoli; Pulmonary Diffu | 1983 |
The single-breath carbon monoxide transfer test 25 years on: a reappraisal. 2--Clinical considerations.
Topics: Carbon Monoxide; Diagnosis, Differential; Environmental Exposure; Humans; Lung Diseases; Pulmonary D | 1983 |
Does the lung work? 4. What does the transfer of carbon monoxide mean?
Topics: Biological Transport; Carbon Monoxide; Humans; Lung; Lung Diseases; Methods; Oxygen; Pulmonary Diffu | 1982 |
[Smoking or health: the choice is yours (author's transl)].
Topics: Bronchitis; Carbon Monoxide; Carcinogens; Female; Heart Diseases; Humans; Irritants; Lung Diseases; | 1980 |
Serial estimations of carbon monoxide diffusing capacity in intrapulmonary haemorrhage.
Topics: Adult; Carbon Monoxide; Child; Hemorrhage; Humans; Lung Diseases; Middle Aged; Pulmonary Diffusing C | 1981 |
Distribution of ventilation and diffusing capacity in the normal and diseased lung.
Topics: Adolescent; Adult; Aged; Air Pressure; Argon; Carbon Monoxide; Female; Helium; Humans; Lung; Lung Di | 1981 |
[Efficacy of gas exchange in the lung of children (author's transl)].
Topics: Adolescent; Carbon Monoxide; Child; Female; Humans; Inspiratory Capacity; Lung; Lung Diseases; Male | 1981 |
Clinical significance of pulmonary function tests. Use and interpretation of the single-breath diffusing capacity.
Topics: Capillary Permeability; Carbon Monoxide; Carboxyhemoglobin; Humans; Lung Diseases; Pulmonary Alveoli | 1980 |
Significance of carbon monoxide pulmonary partial ductances and transbronchial lung biopsies during evolution of interstitial lung diseases.
Topics: Asbestosis; Biopsy; Bird Fancier's Lung; Bronchitis; Bronchoscopy; Carbon Monoxide; Humans; Lung; Lu | 1980 |
Early pulmonary disease in systemic sclerosis: a comparison between carbon monoxide transfer factor and static lung compliance.
Topics: Acute-Phase Proteins; Carbon Monoxide; Humans; Lung Compliance; Lung Diseases; Pulmonary Alveoli; Pu | 1993 |
Comparison of the single breath with the intrabreath method for the measurement of the carbon monoxide transfer factor in subjects with and without airways obstruction.
Topics: Adult; Aged; Breath Tests; Carbon Monoxide; Female; Humans; Lung Diseases; Lung Diseases, Obstructiv | 1995 |
Discrete lung involvement in systemic lupus erythematosus: CT assessment.
Topics: Adult; Bronchial Diseases; Carbon Monoxide; Female; Forced Expiratory Volume; Humans; Lung Diseases; | 1995 |
Simultaneous measurement of pulmonary diffusing capacity for CO and cardiac output by a rebreathing method in patients with pulmonary diseases.
Topics: Adult; Aged; Breath Tests; Carbon Monoxide; Cardiac Output; Female; Heart Diseases; Humans; Lung Dis | 1995 |
Evaluation of a technique for detection of pulmonary hemorrhage in horses, using carbon monoxide uptake.
Topics: Animals; Carbon Monoxide; Diffusion; Functional Residual Capacity; Hemorrhage; Horse Diseases; Horse | 1994 |
A decline in the pulmonary diffusing capacity does not indicate opportunistic lung disease in asymptomatic persons infected with the human immunodeficiency virus. Pulmonary Complications of HIV Infection Study Group.
Topics: Adult; AIDS-Related Opportunistic Infections; Biopsy; Bronchoscopy; Carbon Monoxide; CD4-Positive T- | 1993 |
[Bronchoalveolar lavage and diffusion capacity of carbon monoxide in the diagnosis of diffuse alveolar hemorrhage].
Topics: Bronchoalveolar Lavage Fluid; Carbon Monoxide; Diffusion; Hemorrhage; Humans; Lung Diseases; Pulmona | 1993 |
Clinical correlates of an elevated diffusing capacity for carbon monoxide corrected for alveolar volume.
Topics: Adult; Aged; Blood Volume; Body Mass Index; Carbon Monoxide; Diffusion; Humans; Lung Diseases; Lung | 1996 |
Thoracoscopic laser bullectomy: a prospective study with three-month results.
Topics: Acid-Base Imbalance; Adult; Aged; Blister; Carbon Dioxide; Carbon Monoxide; Dyspnea; Echocardiograph | 1996 |
Toxic gas exposures in ice arenas.
Topics: Air Pollutants; Air Pollution, Indoor; Carbon Monoxide; Environmental Exposure; Environmental Monito | 1996 |
The concept of Raynaud's phenomenon of the lung revisited.
Topics: Adult; Blood Pressure; Carbon Monoxide; Cold Temperature; Female; Humans; Lung Diseases; Lung Volume | 1996 |
Respiratory dysfunction in multiple sclerosis: a prospective analysis of 60 patients.
Topics: Adult; Aged; Brain Stem; Carbon Monoxide; Cerebellum; Female; Forced Expiratory Volume; Humans; Inha | 1997 |
Pulmonary mechanical and immunologic dysfunction in a murine model of AIDS.
Topics: Acquired Immunodeficiency Syndrome; Animals; Carbon Monoxide; Collagen; Cytokines; Disease Models, A | 1997 |
Effect of alveolar volume on the interpretation of single breath DLCO.
Topics: Adult; Blood Gas Analysis; Carbon Monoxide; Female; Humans; Lung Diseases; Male; Pulmonary Alveoli; | 1997 |
Predictive respiratory complication quotient predicts pulmonary complications in thoracic surgical patients.
Topics: Algorithms; Carbon Dioxide; Carbon Monoxide; Cause of Death; Critical Care; Databases as Topic; Fema | 1998 |
Reduction of diffusion capacity for carbon monoxide in diabetic patients.
Topics: Adult; Carbon Monoxide; Chromatography, Ion Exchange; Chronic Disease; Diabetes Complications; Diabe | 1998 |
Method for analysis of exhaled air by microwave energy desorption coupled with gas chromatography-flame ionization detection-mass spectrometry.
Topics: Acetylene; Acute Disease; Adsorption; Anesthetics, Inhalation; Breath Tests; Carbon Dioxide; Carbon | 1998 |
Urban air pollution and cardiopulmonary ill health: a 14.5 year time series study.
Topics: Adult; Aged; Air Pollutants; Carbon Monoxide; Heart Diseases; Humans; Longitudinal Studies; Lung Dis | 1998 |
Association of air pollution with daily GP consultations for asthma and other lower respiratory conditions in London.
Topics: Adolescent; Adult; Aged; Air Pollution; Asthma; Carbon Monoxide; Child; Child, Preschool; Databases, | 1999 |
Cardiomegaly as a possible cause of lung dysfunction in patients with heart failure.
Topics: Aged; Blood Volume; Capillaries; Capillary Permeability; Carbon Monoxide; Cardiomegaly; Female; Forc | 2000 |
[Fractional CO uptake in breathing at risk for detection of diffusion disorder. Comparative cross-sectional and longitudinal validation with the single breath method].
Topics: Breath Tests; Carbon Monoxide; Cross-Sectional Studies; Forced Expiratory Volume; Humans; Longitudin | 2000 |
"Haemoxygenase-1 induction and exhaled markers of oxidative stress in lung diseases", summary of the ERS Research Seminar in Budapest, Hungary, September, 1999.
Topics: Antioxidants; Biomarkers; Breath Tests; Carbon Monoxide; Enzyme Induction; Heme Oxygenase (Decyclizi | 2001 |
A prospective study of pulmonary function in patients treated with paclitaxel and carboplatin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arteries; Carbon Monoxide; Carboplatin; Female | 2002 |
Exhaled markers of inflammation.
Topics: Biomarkers; Breath Tests; Carbon Monoxide; Humans; Hydrocarbons; Inflammation; Leukotrienes; Lung Di | 2001 |
Endogenous carbon monoxide attenuates lung injury following ischemia-reperfusion in the hind limbs of rats.
Topics: Animals; Carbon Monoxide; Carboxyhemoglobin; Heme Oxygenase (Decyclizing); Hindlimb; Lung Diseases; | 2002 |
Carbon monoxide uptake as a test for lung haemorrhage.
Topics: Anti-Glomerular Basement Membrane Disease; Breath Tests; Carbon Monoxide; Hemorrhage; Humans; Lung D | 1977 |
Bedside rebreathing technique for measuring carbon-monoxide uptake by the lung.
Topics: Adult; Aged; Carbon Monoxide; Humans; Lung; Lung Diseases; Middle Aged; Respiratory Function Tests; | 1978 |
Effect of ambient level of carbon monoxide on cardiopulmonary disease.
Topics: Air Pollution; Animals; Carbon Monoxide; Cardiovascular Diseases; Haplorhini; Humans; Lung Diseases | 1978 |
[Measurement of regional pulmonary function with carbon-11-labeled CO2 and CO--studies of radioactive gas clearance curve (author's transl)].
Topics: Adult; Carbon Dioxide; Carbon Monoxide; Carbon Radioisotopes; Female; Humans; Lung; Lung Diseases; M | 1979 |
The clinical usefulness of a screening test to detect static pulmonary blood using a multiple-breath analysis of diffusing capacity.
Topics: Adult; Carbon Monoxide; Carboxyhemoglobin; Hemorrhage; Humans; Lung Diseases; Mass Spectrometry; Pul | 1979 |
The chest X-ray in pulmonary capillary haemorrhage: correlation with carbon monoxide uptake.
Topics: Adolescent; Adult; Anti-Glomerular Basement Membrane Disease; Carbon Monoxide; Child; Female; Hemorr | 1979 |
Ventilatory function in the Eisenmenger syndrome.
Topics: Adult; Carbon Monoxide; Eisenmenger Complex; Female; Humans; Lung; Lung Diseases; Lung Volume Measur | 1979 |
Interpretation of increases in the transfer coefficient for carbon monoxide (TLCO/VA or KCO).
Topics: Adult; Carbon Monoxide; Hemorrhage; Humans; Lung; Lung Diseases; Respiratory Function Tests; Vital C | 1978 |
Pulmonary hemorrhage in Goodpasture's syndrome.
Topics: Anti-Glomerular Basement Membrane Disease; Autoantibodies; Basement Membrane; Carbon Monoxide; Hemor | 1977 |
Detection of intrapulmonary hemorrhage with carbon monoxide uptake. Application in goodpasture's syndrome.
Topics: Adolescent; Adult; Anti-Glomerular Basement Membrane Disease; Breath Tests; Carbon Monoxide; Diagnos | 1976 |
Pulmonary function in stage I and II pulmonary sarcoidosis.
Topics: Airway Resistance; Carbon Monoxide; Forced Expiratory Volume; Humans; Lung; Lung Diseases; Maximal M | 1976 |
Single-breath pulmonary diffusing capacity. Reference values and application in connective tissue diseases and in various lung diseases.
Topics: Adult; Aged; Arthritis, Rheumatoid; Biopsy, Needle; Carbon Monoxide; Collagen Diseases; Female; Hemo | 1976 |
[Air pollution and the lungs; present and future risks (author's transl)].
Topics: Air Pollutants; Air Pollution; Carbon Monoxide; Dust; Germany, West; Humans; Lung Diseases; Sulfur D | 1975 |
Respiratory effects of cocaine freebasing among habitual cocaine users.
Topics: Adult; Carbon Monoxide; Crack Cocaine; Female; Humans; Lung; Lung Diseases; Male; Mediastinal Emphys | 1992 |
Management of dysfunction in the transplanted lung: experience with 7 clinical cases. Washington University Lung Transplant Group.
Topics: Adult; Anastomosis, Surgical; Carbon Monoxide; Cohort Studies; Critical Care; Follow-Up Studies; For | 1992 |
Lung function in primary Sjögren's syndrome: a cross sectional and longitudinal study.
Topics: Adolescent; Adult; Aged; Carbon Monoxide; Cross-Sectional Studies; Female; Forced Expiratory Volume; | 1991 |
Diffusing capacity of the lung and nifedipine in systemic sclerosis.
Topics: Adult; Carbon Monoxide; Drug Administration Schedule; Female; Hemodynamics; Humans; Lung Diseases; M | 1990 |
Pulmonary complications of multimodality therapy for esophageal carcinoma.
Topics: Bleomycin; Breath Tests; Carbon Monoxide; Carcinoma, Squamous Cell; Combined Modality Therapy; Esoph | 1987 |
Pulmonary function and symptoms after inhalation of endotoxin.
Topics: Aerosols; Bronchial Provocation Tests; Carbon Dioxide; Carbon Monoxide; Endotoxins; Enterobacter; En | 1989 |
Alveolar haemorrhage.
Topics: Carbon Monoxide; Hemorrhage; Hemosiderosis; Humans; Lung Diseases; Pulmonary Alveoli | 1985 |
Cobalt exposure and lung disease in tungsten carbide production. A cross-sectional study of current workers.
Topics: Carbon Monoxide; Cobalt; Cross-Sectional Studies; Forced Expiratory Volume; Humans; Lung Diseases; M | 1988 |
The alveolar carbon monoxide uptake fraction: a simple, alternative measure of carbon monoxide transfer.
Topics: Carbon Monoxide; Carboxyhemoglobin; Forced Expiratory Volume; Humans; Lung Diseases; Oxygen Consumpt | 1988 |
Diffusing capacity for carbon monoxide as a predictor of gas exchange during exercise.
Topics: Asbestosis; Carbon Monoxide; Humans; Lung Diseases; Lung Diseases, Obstructive; Male; Middle Aged; P | 1987 |
Indoor and outdoor air pollutants and health.
Topics: Adult; Air Pollutants; Animals; Carbon Monoxide; Child; Formaldehyde; Humans; Lung Diseases; Nitroge | 1987 |
Recurrent diffuse pulmonary hemorrhage with minor kidney lesions.
Topics: Adolescent; Anti-Glomerular Basement Membrane Disease; Carbon Monoxide; Complement C3; Hemoptysis; H | 1985 |
[Diagnostic imaging by radioisotopes. Application (X). Evaluation of regional pulmonary function using short-lived radioactive gases].
Topics: Aged; Carbon Dioxide; Carbon Monoxide; Carbon Radioisotopes; Electrons; Gases; Humans; Isotope Label | 1985 |
[Steady-state carbon monoxide transfer during progressive muscular exercise in patients. Relation to PaO2. Value of specific VCO].
Topics: Aging; Carbon Monoxide; Humans; Hypoxia; Lung Diseases; Lung Diseases, Obstructive; Male; Middle Age | 1985 |
Smoking cessation in chronically ill medical patients.
Topics: Behavior Therapy; Carbon Monoxide; Chronic Disease; Coronary Disease; Feedback; Follow-Up Studies; H | 1985 |
[Scandinavian seminar: environmental pollution and heart and lung diseases].
Topics: Adult; Air Pollutants; Air Pollution; Asbestos; Asthma; Bronchitis; Carbon Monoxide; Child; Environm | 1974 |
[Comparative study of Co transfer factor as determined by the single-breath and steady-state method (author's transl)].
Topics: Adult; Aged; Carbon Monoxide; Humans; Lung Diseases; Male; Middle Aged; Pulmonary Diffusing Capacity | 1974 |
Azathioprin nd acute restrictive lung disese.
Topics: Acute Disease; Adult; Azathioprine; Carbon Monoxide; Colitis, Ulcerative; Cough; Dyspnea; Humans; Lu | 1972 |
[Problems in the diffusing capacity of the lung].
Topics: Carbon Monoxide; Humans; Lung Diseases; Models, Theoretical; Oxygen; Pulmonary Diffusing Capacity | 1972 |
Toxicity of long-term exposure to oxides of sulfur.
Topics: Animals; Blood Cell Count; Body Weight; Carbon Monoxide; Dogs; Drug Synergism; Environmental Exposur | 1973 |
A new method of measuring pulmonary diffusing capacity for oxygen in patients with diffuse lung disease.
Topics: Adolescent; Adult; Carbon Monoxide; Female; Humans; Hypoxia; Lung Diseases; Male; Methods; Middle Ag | 1973 |
[Evaluation of pulmonary diffusing capacity by the ergometric method of Rossier and Bühlmann and the "Steady-State" diffusing capacity for carbon monoxide of Filley (author's transl)].
Topics: Adolescent; Adult; Age Factors; Aged; Airway Resistance; Blood Gas Analysis; Carbon Monoxide; Exerci | 1973 |
[Steady-state CO pulmonary diffusing capacity in chronic pulmonary diseases].
Topics: Adolescent; Adult; Carbon Monoxide; Chronic Disease; Female; Humans; Lung Diseases; Male; Middle Age | 1973 |
Pulmonary function in alcoholics.
Topics: Adult; Alcoholism; Bronchitis; Carbon Monoxide; Disease Susceptibility; Dyspnea; Ethanol; Female; Hu | 1974 |
["Steady-state" diffusing capacity of Filley in relation to the time of carbon monoxide breathing (author's transl)].
Topics: Adult; Aged; Blood Gas Analysis; Carbon Monoxide; Carboxyhemoglobin; Humans; Lung Diseases; Lung Dis | 1974 |
Ventilation rate and end--tidal steady state pulmonary diffusing capacity (DLCOSS2) at rest.
Topics: Adult; Aged; Carbon Dioxide; Carbon Monoxide; Carboxyhemoglobin; Chromatography, Gas; Female; Humans | 1974 |
Single-breath gas distribution in chronic obstructive lung disease. Isoproterenol effect on neon dilution volume and diffusing capacity.
Topics: Adult; Airway Resistance; Asthma; Bronchitis; Carbon Monoxide; Diffusion; Female; Humans; Indicator | 1971 |
[The total pulmonary capacity measured from radiographic films. Clinical value].
Topics: Adult; Aged; Carbon Monoxide; Female; Helium; Humans; Lung; Lung Diseases; Male; Middle Aged; Radiog | 1972 |
Alveolar-capillary membrane in pulmonary sarcoidosis: an electron microscopic study.
Topics: Adult; Biopsy; Capillaries; Carbon Monoxide; Cell Membrane; Female; Humans; Lung; Lung Diseases; Mal | 1972 |
[The effects of solid, liquid and gaseous pollutants on the lung].
Topics: Adaptation, Physiological; Aerosols; Air Pollution; Animals; Carbon Monoxide; Dust; Environmental Ex | 1971 |
Effect of lung volume on steady state pulmonary membrane diffusing capacity and pulmonary capillary blood volume.
Topics: Adult; Air; Blood Volume; Capillaries; Carbon Monoxide; Female; Humans; Hyperventilation; Lung Disea | 1971 |
Exchange transfusion with dextran 40 in polycythaemia secondary to hypoxic lung disease.
Topics: Aged; Blood Viscosity; Blood Volume; Bronchitis; Carbon Dioxide; Carbon Monoxide; Chromium; Dextrans | 1971 |
[Xenon 133 investigation of gas absorption in the lungs].
Topics: Carbon Monoxide; Humans; Lung Diseases; Permeability; Radioisotopes; Respiratory Function Tests; Res | 1971 |
Relation between single-breath diffusing capacity and arterial blood gases in chronic obstructive lung disease.
Topics: Adult; Aged; Carbon Monoxide; Chronic Disease; Diffusion; Female; Granuloma; Humans; Hypoxia; Lung D | 1968 |
On the prediction of pulmonary diffusing capacity with a steady state carbon monoxide method in chronic lung diseases.
Topics: Adult; Aged; Carbon Monoxide; Chronic Disease; Diffusion; Female; Heart Rate; Humans; Lung Diseases; | 1969 |
Relation between rebreathing CO-diffusing capacity of the lung and unequal ventilation.
Topics: Adult; Aged; Carbon Dioxide; Carbon Monoxide; Chronic Disease; Diffusion; Female; Helium; Humans; Lu | 1970 |
Long-term continuous exposure of guinea pigs to sulfur dioxide.
Topics: Air Pollution; Animals; Biological Assay; Body Weight; Carbon Monoxide; Environmental Exposure; Fema | 1970 |
Reproducibility of the carbon monoxide diffusion capacity method.
Topics: Carbon Monoxide; Diffusion; Humans; Lung Diseases; Methods; Pulmonary Diffusing Capacity; Respirator | 1971 |
Organization of a hospital routine pulmonary function laboratory.
Topics: Adolescent; Adult; Aged; Asthma; Blood Gas Analysis; Bronchitis; Carbon Dioxide; Carbon Monoxide; Ch | 1968 |
Application of the single-breath method of total lung capacity measurement to the calculation of the carbon monoxide diffusing capacity.
Topics: Adult; Aged; Carbon Monoxide; Chronic Disease; Helium; Humans; Lung; Lung Diseases; Male; Methods; M | 1968 |
[Fatal poisoning by silo gases (carbon monoxide and oxides of nitrogen)].
Topics: Agricultural Workers' Diseases; Carbon Monoxide; Carbon Monoxide Poisoning; Chromatography, Gas; Hum | 1968 |
Bullous disease of the lung. Physiologic improvement after surgery.
Topics: Adult; Bronchitis; Carbon Dioxide; Carbon Monoxide; Female; Humans; Lung; Lung Diseases; Male; Middl | 1968 |
Air pollution in native huts in the highlands of New Guinea.
Topics: Air Pollution; Aldehydes; Altitude; Architecture; Black People; Carbon Monoxide; Environmental Expos | 1968 |
[Diffusing capacity of the lung and compliance in chronic pulmonary diseases].
Topics: Adolescent; Adult; Carbon Monoxide; Female; Humans; Lung; Lung Compliance; Lung Diseases; Male; Midd | 1968 |
Pulmonary diffusing capacity-- A CRITICAL REVIEW OF ITS VALUE AS A LUNG FUNCTION TEST.
Topics: Blood Flow Velocity; Capillaries; Carbon Dioxide; Carbon Monoxide; Diffusion; Hemoglobins; Humans; L | 1968 |
Aetiological factors in pulmonary oxygen toxicity.
Topics: Animals; Carbon Monoxide; Hyperbaric Oxygenation; Lung Diseases; Mice; Nitrogen; Oxygen | 1969 |
Pulmonary function in pigeon breeders' disease: a hypersensitivity pneumonitis.
Topics: Adult; Animals; Carbon Monoxide; Columbidae; Diffusion; Humans; Lung Compliance; Lung Diseases; Male | 1969 |
Diffusion and impaired gas exchange.
Topics: Blood Gas Analysis; Carbon Monoxide; Humans; Hypoxia; Lung Diseases; Pulmonary Circulation; Respirat | 1965 |
On the influence of body position on steady-state diffusing capacity during exercise, studied in patients with pulmonary sarcoidosis.
Topics: Adult; Carbon Monoxide; Exercise Test; Female; Humans; Lung Diseases; Lung Neoplasms; Lymphoma; Male | 1966 |
Studies on the distribution of the pulmonary arterial blood flow in the lungs by radioisotope scanning. IV. Pulmonary sarcoidosis: the distribution of the pulmonary arterial blood flow with special reference to pulmonary function.
Topics: Adolescent; Adult; Carbon Monoxide; Child; Female; Humans; Lung Diseases; Male; Pulmonary Artery; Pu | 1966 |